<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Stem Cells Int</journal-id><journal-id journal-id-type="iso-abbrev">Stem Cells Int</journal-id><journal-id journal-id-type="publisher-id">SCI</journal-id><journal-title-group><journal-title>Stem Cells International</journal-title></journal-title-group><issn pub-type="ppub">1687-966X</issn><issn pub-type="epub">1687-9678</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4433683</article-id><article-id pub-id-type="doi">10.1155/2015/141793</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>MicroRNA Regulation of Brain Tumour Initiating Cells in Central Nervous System Tumours</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2227-8292</contrib-id><name><surname>Garg</surname><given-names>Neha</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vijayakumar</surname><given-names>Thusyanth</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bakhshinyan</surname><given-names>David</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Venugopal</surname><given-names>Chitra</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Sheila K.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, ON, Canada L8S 4K1</aff><aff id="I2"><sup>2</sup>Department of Surgery, Faculty of Health Sciences, McMaster University, 1200 Main Street West, Hamilton, ON, Canada L8N 3Z5</aff><aff id="I3"><sup>3</sup>Department of Biochemistry and Biomedical Sciences, Faculty of Health Sciences, McMaster University, 1200 Main Street West, Hamilton, ON, Canada L8N 3Z5</aff><aff id="I4"><sup>4</sup>Michael G. DeGroote School of Medicine, McMaster University, 1200 Main Street West, Hamilton, ON, Canada L8N 3Z5</aff><author-notes><corresp id="cor1">*Neha Garg: <email>nehagarg.1986@gmail.com</email></corresp><fn fn-type="other"><p>Academic Editor: Benedetta Bussolati</p></fn></author-notes><pub-date pub-type="ppub"><year>2015</year></pub-date><pub-date pub-type="epub"><day>3</day><month>5</month><year>2015</year></pub-date><volume>2015</volume><elocation-id>141793</elocation-id><history><date date-type="received"><day>23</day><month>1</month><year>2015</year></date><date date-type="rev-recd"><day>19</day><month>3</month><year>2015</year></date><date date-type="accepted"><day>10</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 Neha Garg et al.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>CNS tumours occur in both pediatric and adult patients and many of these tumours are associated with poor clinical outcome. Due to a paradigm shift in thinking for the last several years, these tumours are now considered to originate from a small population of stem-like cells within the bulk tumour tissue. These cells, termed as brain tumour initiating cells (BTICs), are perceived to be regulated by microRNAs at the posttranscriptional/translational levels. Proliferation, stemness, differentiation, invasion, angiogenesis, metastasis, apoptosis, and cell cycle constitute some of the significant processes modulated by microRNAs in cancer initiation and progression. Characterization and functional studies on oncogenic or tumour suppressive microRNAs are made possible because of developments in sequencing and microarray techniques. In the current review, we bring recent knowledge of the role of microRNAs in BTIC formation and therapy. Special attention is paid to two highly aggressive and well-characterized brain tumours: gliomas and medulloblastoma. As microRNA seems to be altered in the pathogenesis of many human diseases, &#x0201c;microRNA therapy&#x0201d; may now have potential to improve outcomes for brain tumour patients. In this rapidly evolving field, further understanding of miRNA biology and its contribution towards cancer can be mined for new therapeutic tools.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>MicroRNAs are small (19&#x02013;25 nucleotides) noncoding RNAs that bind within the 3&#x02032; untranslated region (UTR) of protein coding mRNAs [<xref rid="B1" ref-type="bibr">1</xref>] and regulate gene expression. This sequence-dependent posttranscriptional regulation of gene expression occurs either by repressing translation or degradation of target mRNAs [<xref rid="B2" ref-type="bibr">2</xref>]. Recently, a novel regulatory mechanism to regulate transcription or stimulate translation by binding to gene promoters or 3&#x02032;- and 5&#x02032;-UTRs of mRNAs, respectively, is attributed to miRNAs [<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>]. As far as their biogenesis is concerned, when miRNA sequences are transcribed, they are formulated into hairpin-like structures called pri-microRNAs [<xref rid="B5" ref-type="bibr">5</xref>]. The primary transcripts are initially cleaved by a RNase III enzyme known as Drosha in the nucleus, which leads to the production of precursor miRNAs (pre-miRNAs) [<xref rid="B5" ref-type="bibr">5</xref>]. Once the pre-miRNAs are transported into the cytoplasm, a second set of RNase III Dicer enzymes cleave the transcript to produce mature miRNAs [<xref rid="B6" ref-type="bibr">6</xref>]. miRNAs are associated with RNA-induced silencing complex (RISC) before they can acquire the full ability to bind their target mRNA [<xref rid="B7" ref-type="bibr">7</xref>]. Each miRNA can target multiple transcripts and together all the miRNAs are postulated to regulate about one-third of the human genome [<xref rid="B8" ref-type="bibr">8</xref>].</p></sec><sec id="sec2"><title>2. Deregulation of MicroRNAs in Cancer</title><p>Many human diseases, including cancer, have aberrant miRNA expression compared to normal healthy individuals [<xref rid="B9" ref-type="bibr">9</xref>]. In recent years, researchers have uncovered modifications at the level of genome processing. Genetic and epigenetic changes in the genome or amplification or deletion of regions can contribute to deregulation of microRNA levels [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. It has been predicted that about 45% of all pre-miRNAs have a minimum of one transcription factor binding site motif. The transcription factors can bind at conventional binding sites on the promoter of pre-miRNAs or have the ability to regulate microRNA processing by binding directly to the pri-miR and/or pre-miR [<xref rid="B12" ref-type="bibr">12</xref>]. An example is shown by the presence of Smad binding elements in pre-miRNAs responsive to TGF-<italic>&#x003b2;</italic>/BMP-4 stimulation [<xref rid="B13" ref-type="bibr">13</xref>]. Other examples for miRNA regulators include p53 [<xref rid="B14" ref-type="bibr">14</xref>], E2F [<xref rid="B15" ref-type="bibr">15</xref>], and Myc [<xref rid="B16" ref-type="bibr">16</xref>], the most common transcription factors for cell cycle regulation and guarding the genome. CpG hypermethylation [<xref rid="B17" ref-type="bibr">17</xref>] and aberrant enzymes/components of microRNA processing like Dicer or Drosha [<xref rid="B18" ref-type="bibr">18</xref>] also have the potential to regulate miRNAs. miRNAs can modulate all the &#x0201c;hallmarks of cancer&#x0201d; described by Hanahan and Weinberg, that is, uncontrolled proliferation, resisting apoptosis, and stimulating new pathways that can help in cancer invasion and metastasis like angiogenesis [<xref rid="B19" ref-type="bibr">19</xref>]. Therefore, microRNAs, although small, are critical regulators of cancer initiation and progression, and in the subsequent sections we will discuss their role in brain tumour initiation in more detail.</p></sec><sec id="sec3"><title>3. Cancer Stem Cell Hypothesis and Brain Tumour Initiating Cells</title><p>Many solid tumours are composed of varied cell types including vascular tissues, inflammatory cells, neighboring fibroblasts, and neoplastic/cancerous cells [<xref rid="B20" ref-type="bibr">20</xref>]. The majority of cells may not drive tumour formation, whereas a minority of stem cells population within the tumour is exclusively capable of self-renewal and driving tumour growth. These cells are termed as cancer stem cells (CSCs) or tumour initiating cells (TICs) [<xref rid="B21" ref-type="bibr">21</xref>]. This elegant concept has reemerged only recently, although its origin can be traced to 1855 [<xref rid="B22" ref-type="bibr">22</xref>]. The first CSCs were described in acute myeloid leukemia (AML) [<xref rid="B23" ref-type="bibr">23</xref>]. To prevent the tumour from relapse after standard oncology treatments, many cancer therapies are now focused on eradication of CSCs. Therefore a complete molecular and physiological understanding of CSCs in their niche is needed to achieve this goal.</p><p>After the initial discovery of prospective breast cancer stem cells [<xref rid="B24" ref-type="bibr">24</xref>], brain tumour initiating cells (BTICs) [<xref rid="B25" ref-type="bibr">25</xref>] were characterized, raising the possibility of a hierarchical organization of solid tumours. Furthermore, these rare BTICs were able to reproduce a complete heterogeneous cancer that is of similar composition as the original cancer from which it was harvested [<xref rid="B25" ref-type="bibr">25</xref>]. BTICs that can be distinguished, based on their abnormal stem cell-like properties, can further be identified based on markers. CD133, also referred to as prominin-1 (PROM1), is a pentaspan transmembrane cell surface protein which has gained popularity as a CSC marker [<xref rid="B25" ref-type="bibr">25</xref>]. The initial work applying CD133 as a BTIC marker supported CSCs to be highly associated with CD133 expression [<xref rid="B25" ref-type="bibr">25</xref>]. The CD133+ subpopulation within a heterogeneous GBM culture has been proven to exhibit stem-like properties such as self-renewal, high proliferation, and multipotency and at the same time this population has increased resistance to radiation treatments in comparison to CD133- GBM cells [<xref rid="B26" ref-type="bibr">26</xref>&#x02013;<xref rid="B29" ref-type="bibr">29</xref>]. Although CD133 has been utilized as a BTIC marker, much is still unknown of this protein at the functional level. Further research in the past several years alluded to the discovery of additional markers such as CD15. CD15, also known as stage-specific embryonic antigen-1 (SSEA-1) or Lewis X, was initially assessed as a marker for neural stem cells (NSCs) and neural precursor cells (NPCs) in the brain [<xref rid="B30" ref-type="bibr">30</xref>]. In a mouse model of medulloblastoma, it was postulated that CD15+ cells were more effective at propagating tumours in comparison to CD133+ cells [<xref rid="B31" ref-type="bibr">31</xref>]. However, it is still conceded by multiple studies that the combination of evaluating both of these markers would provide a more accurate identification of BTICs [<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>]. The aforementioned CD133 and CD15 and even other novel proteins such as CD271 are categorized as external markers of BTICs and are used in various staining techniques to isolate them [<xref rid="B33" ref-type="bibr">33</xref>]. Recent research has also uncovered many cell-intrinsic markers that mark cells with tumorigenic properties. Many of these novel markers have been previously described as NSC markers. One of these, Bmi1, is a member of the polycomb group proteins, which is notably involved in self-renewal of NSCs and CSCs through means of repressing the<italic> INK4a/ARF</italic> locus [<xref rid="B34" ref-type="bibr">34</xref>]. Other more regularly used internal markers of BTICs include Sox2, FoxG1, Oct4, Twist1, and Nestin [<xref rid="B35" ref-type="bibr">35</xref>&#x02013;<xref rid="B38" ref-type="bibr">38</xref>]. Nanog, a transcription factor involved in maintaining self-renewal of embryonic [<xref rid="B39" ref-type="bibr">39</xref>] and adult neural stem cells [<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>], has also been shown to provide stemness in BTICs [<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>]. Aldehyde dehydrogenase (ALDH) is an enzyme that plays a critical role in the metabolism and detoxification of external and internal substances. ALDH has also been found to be highly upregulated not only in NSCs but also in BTICs [<xref rid="B43" ref-type="bibr">43</xref>]. ALDH contributes to high proliferation rate and increased resistance to chemotherapy and radiation of BTICs [<xref rid="B43" ref-type="bibr">43</xref>]. Thus, ALDH is considered to be a BTIC marker. Other markers of BTICs include ABCG2, a key member within the ABC transporter family. This marker plays a potential role in multidrug resistance [<xref rid="B44" ref-type="bibr">44</xref>]. These transporters are highly expressed in CSCs and act to prevent the deterioration of these cells by means of blocking xenobiotic toxins [<xref rid="B44" ref-type="bibr">44</xref>].</p></sec><sec id="sec4"><title>4. MicroRNAs in Brain Tumour Initiating Cells</title><p>miRNAs play an important role in cellular development and growth. However, in the case of cancers, aberrant miRNA levels may play a functional role in pathogenesis. Despite evidence for the key roles that miRNAs play in brain tumour pathogenesis [<xref rid="B45" ref-type="bibr">45</xref>], clinically relevant knowledge of the prognostic, diagnostic, and therapeutic potential of these RNA particles in BTICs is yet to be elucidated. The implications of miRNAs in BTICs of CNS tumour for both pediatric and adult patients are discussed below.</p></sec><sec id="sec5"><title>5. Gliomas</title><p>Gliomas are divided according to their histological features into four grades by World Health Organization (2007) [<xref rid="B46" ref-type="bibr">46</xref>]. This classification from grade I to grade IV also stratifies gliomas from slow developing tumours to highly aggressive and infiltrative ones. The most aggressive grade IV glioma and accounting for almost half of the gliomas is Glioblastoma (GBM) [<xref rid="B47" ref-type="bibr">47</xref>]. GBM patients have a 5-year survival rate of less than 10% [<xref rid="B48" ref-type="bibr">48</xref>] despite advanced treatments with a combination of surgery, radiotherapy, and chemotherapy. As in the case of majority of brain tumours, selective cells within tumours are responsible for initiation and maintenance of gliomas and these are termed as glioma stem cells (GSCs) [<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B28" ref-type="bibr">28</xref>]. The first study that described GSCs used surgical specimens of patient GBMs and characterized stem cell populations through neurosphere and clonogenic assays [<xref rid="B49" ref-type="bibr">49</xref>]. From then, there has been robust knowledge development in comparing normal stem cells and BTICs responsible for gliomas. These similarities are based on shared characteristics such as self-renewal, proliferation, differentiation, and expression of cell surface and internal markers including CD133, CD15, Bmi1, Nestin, Nanog, and Oct4 [<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>]. Although there is some controversy with respect to the functional significance and labelling of GSCs, methods such as side population analysis [<xref rid="B52" ref-type="bibr">52</xref>], marker characterization, and use of<italic> in vitro</italic> culture [<xref rid="B28" ref-type="bibr">28</xref>] are useful tools for the enrichment and analysis of GSCs. Further studies of regulatory mechanisms underpinning GSCs are therefore warranted, and, more recently, there has been an increased focus on the functional role of microRNA (miRNA) in GSCs [<xref rid="B53" ref-type="bibr">53</xref>].</p><p>Ciafr&#x000e8; et al. and Chan et al. performed the first studies on miRNA expression profiles in GBM in 2005. Ciafr&#x000e8; et al. [<xref rid="B54" ref-type="bibr">54</xref>] demonstrated aberrant expression profiles of numerous miRNAs such as miR-221 which were strongly upregulated in GBM and miRNAs such as miR-128, miR-181a, miR-181b, and miR-181c which were shown to be downregulated in GBM. Chan et al. [<xref rid="B55" ref-type="bibr">55</xref>] also investigated the functional properties of miR-21 as an oncogenic microRNA. Since then, large-scale studies on GBM and GSCs were performed to elucidate miRNA-mediated mechanisms of tumorigenesis.</p></sec><sec id="sec6"><title>6. miRNAs as Tumour Suppressors in GBM</title><p>In human U251 GSCs, miR-125b was amongst the first few microRNAs found to be downregulated and shown to play a role in GSC maintenance [<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B57" ref-type="bibr">57</xref>]. miR-125b overexpression was found to decrease the expression of cell cycle regulatory proteins, CDK6 and CDC25A, thereby preventing cell cycle arrest at the G1/S transition [<xref rid="B56" ref-type="bibr">56</xref>]. Another group reported the downregulation of miR-125b in CD133+ GSCs [<xref rid="B58" ref-type="bibr">58</xref>]. This downregulation of miR-125b leads to E2F2 expression and cell cycle progression [<xref rid="B58" ref-type="bibr">58</xref>]. An alternate mechanism described the effects of miR-125b on the invasion of CD133+ GSCs cells. The changes in expression of matrix metalloproteinases (MMP-2 and MMP-9) and their corresponding inhibitors (RECK and TIMP3) by miR-125b aid GSCs to infiltrate the brain [<xref rid="B56" ref-type="bibr">56</xref>].</p><p>Oncogenic receptor tyrosine kinases epithelial growth factor receptor (EGFR) and platelet-derived growth factor receptor-a (PDGFR) are targeted by miR-128 [<xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B60" ref-type="bibr">60</xref>]. Recent studies showed that miR-128 also modulates other mitogenic kinases such as oncogenic receptor tyrosine kinases (RTKs) in gliomas [<xref rid="B60" ref-type="bibr">60</xref>]. Overexpression of miR-128 is accompanied by a decrease in histone methylation H3K27me(3) and Akt phosphorylation [<xref rid="B59" ref-type="bibr">59</xref>]. In addition, Bmi1, a stem cell marker and an oncogene, is directly targeted by miR-128 [<xref rid="B59" ref-type="bibr">59</xref>]. Overexpression of miR-128 was shown to downregulate the activity of p70S6K1 and expression of its downstream signaling molecules such as HIF-1 and VEGF and reduced cell proliferation, tumour growth, and angiogenesis [<xref rid="B61" ref-type="bibr">61</xref>]. p70S6K1, a key downstream target of mammalian rapamycin (mTOR), is a direct target of miR-128 which plays a role in glioma tumour angiogenesis [<xref rid="B61" ref-type="bibr">61</xref>]. Transcription factor E2F3 was also reported as a target of miR-128 in glioma cells [<xref rid="B62" ref-type="bibr">62</xref>].</p><p>Many other miRNAs also function primarily as tumour suppressors. Overexpression of miR-143 inhibited glycolysis, promoted differentiation, and decreased tumorigenic capacity of GSCs<italic> in vivo</italic>, underscoring its important role as a tumour suppressor [<xref rid="B63" ref-type="bibr">63</xref>]. The expression of miR-153 that functions as an oncosuppressor was found to be downregulated in GBM tissues and in cultured CD133+ GSCs. Transfection of miR-153 into these GSCs induced differentiation and apoptosis and stalled tumour growth [<xref rid="B64" ref-type="bibr">64</xref>]. miR-7 was implicated in GBM as a tumor suppressor by regulating epidermal growth factor receptor (EGFR) and the Akt pathway. Moreover, miR-7 transfection was shown to decrease viability and invasiveness of GBM cells [<xref rid="B65" ref-type="bibr">65</xref>]. Recently, miR-145 was shown to inhibit migration and invasion of GSCs by targeting ATP-binding cassette transporter protein (ABCG2) [<xref rid="B66" ref-type="bibr">66</xref>]. This microRNA is normally expressed in neurons but has reduced expression in GBMs [<xref rid="B66" ref-type="bibr">66</xref>].</p><p>The universal anticancer gene, p53, is also linked to microRNAs in GSCs. miR-34a expression was downregulated in mutant p53 gliomas as compared with wild-type p53 gliomas [<xref rid="B67" ref-type="bibr">67</xref>]. miR-34a transfection inhibited survival, proliferation, cell cycle progression, cell invasion, and<italic> in vivo</italic> glioma xenograft growth and induces differentiation in GSCs [<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B68" ref-type="bibr">68</xref>]. In addition, a recent report suggested that miRNA-34a regulates Akt and Wnt signaling pathways to suppress the proliferation and tumor growth of GSCs [<xref rid="B69" ref-type="bibr">69</xref>]. Oncogenes such as c-Met, Notch-1, and Notch-2 are the direct targets of miR-34a in GSCs [<xref rid="B68" ref-type="bibr">68</xref>]. Other members of miR-34 family, that is, miR-34c-3p and miR-34c-5p, also affect proliferation and invasion of glioma cells but with a differential activity [<xref rid="B70" ref-type="bibr">70</xref>].</p><p>Many microRNAs function effectively in modulating cell signaling. Downregulation of Notch-1 by miR-146a in GBM decreases migration of GSCs, thereby classifying miR-146a as an oncosuppressor [<xref rid="B71" ref-type="bibr">71</xref>]. miR-107 was reported to Notch-2 by Chen et al. in 2013 [<xref rid="B72" ref-type="bibr">72</xref>]. miR-326 was shown to reduce growth, invasion, and tumorigenicity of GBM stem cells by targeting Notch-1, Notch-2, and pyruvate kinase muscle enzyme (PKM2) [<xref rid="B73" ref-type="bibr">73</xref>]. miR-107 suppressed proliferation, downregulated stem cell markers (CD133 and Nestin), reduced MMP-12 expression, and concealed GSCs xenograft growth<italic> in vivo</italic> [<xref rid="B72" ref-type="bibr">72</xref>]. In glioma cells, miR-622 inhibited tumor invasion and migration by targeting activating transcription factor 2 (ATF2) [<xref rid="B74" ref-type="bibr">74</xref>].<italic> In vivo</italic> as well as<italic> in vitro</italic> data explored the role of miR-152 as a tumor suppressor in GBM stem cells [<xref rid="B75" ref-type="bibr">75</xref>]. Kr&#x000fc;ppel-like factor 4 (KLF4) was suggested as the downstream target of miR-152. The downregulation of KLF4 by overexpressing miR-152 leads to attenuation of the activation of MEK1/2 and PI3K signal pathways [<xref rid="B75" ref-type="bibr">75</xref>]. miR-218 is one of the commonly downregulated microRNAs in GSCs [<xref rid="B76" ref-type="bibr">76</xref>] which targets Bmi1. This again emphasizes the fact that microRNAs regulate key molecules in GSCs [<xref rid="B76" ref-type="bibr">76</xref>].</p><p>miR-124 and miR-137 are two oncosuppressors whose overexpression can induce differentiation and G1 cell cycle arrest of GSCs [<xref rid="B77" ref-type="bibr">77</xref>]. Both microRNAs bind to CDK6, a G1/S cell cycle regulator, and thereby induce differentiation of GSCs [<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B77" ref-type="bibr">77</xref>]. Overexpression of miR-124 resulted in targeting of Neural Crest Transcription Factor Slug (SNAI2), which in turn inhibits tumorigenicity of gliomas and invasion<italic> in vivo</italic> [<xref rid="B78" ref-type="bibr">78</xref>]. Glioma pathogenesis-related protein 1(GLIPR1) or RTVP-1 is a direct target of miR-137 and this is another mechanism by which miR-137 inhibits stemness in GSCs [<xref rid="B79" ref-type="bibr">79</xref>]. A recent report shows the broader impact of miR-137 by regulating multiple genes in GBM. Using high throughput RNA sequencing (RNAseq) and RNA-binding protein immunoprecipitation sequencing (RIPseq), the authors have predicted miR-137 targets such as c-KIT, YBX1, Akt2, CDC42, CDK6, and TGF<italic>&#x003b2;</italic>2 [<xref rid="B80" ref-type="bibr">80</xref>]. miR-451 is reported to suppress tumour growth both in gliomas [<xref rid="B81" ref-type="bibr">81</xref>] and GBM stem cells [<xref rid="B82" ref-type="bibr">82</xref>].</p><p>Last but not least, members of the microRNA miR-200 family are key regulators of cell proliferation, cell cycle, and tumour growth in gliomas and GSCs. In gliomas, miR-200b suppresses tumour cell growth by targeting the CREB1 gene [<xref rid="B83" ref-type="bibr">83</xref>]. Low expression levels of miR-200b are linked with poor prognosis in glioma patients [<xref rid="B84" ref-type="bibr">84</xref>]. In gliomas, miR-200b also targets multiple members of RAB family [<xref rid="B85" ref-type="bibr">85</xref>]. Another member of miR-200 family, miR-200a, downregulates single-minded homolog 2-short form (SIM2-s) [<xref rid="B86" ref-type="bibr">86</xref>]. SIM2-s is elevated in many human cancers and in gliomas; it facilitates tumour growth and invasion [<xref rid="B86" ref-type="bibr">86</xref>].</p></sec><sec id="sec7"><title>7. miRNAs as Oncogenes in GBM</title><p>Alternative classes of microRNAs called oncomiRs or oncogenic microRNAs were found to be deregulated in GSCs. These include the miR-10 family [<xref rid="B87" ref-type="bibr">87</xref>] (miR-10a and miR-10b) and miR-17-92 cluster. Repressed expression of tumour suppressor genes CUB and SUSHI was observed upon upregulation of miR-10 family members [<xref rid="B87" ref-type="bibr">87</xref>]. As described by Guessous et al., miR-10b inhibition significantly diminishes<italic> in vivo</italic> tumour formation and also reduces proliferation and invasion of GSCs [<xref rid="B88" ref-type="bibr">88</xref>]. The first oncomiR cluster miR-17-92 [<xref rid="B89" ref-type="bibr">89</xref>] and miR-9 were found to be enriched in GSCs. The miR-9 target calmodulin-binding transcription activator 1 (CAMTA1) functions as a tumor suppressor [<xref rid="B90" ref-type="bibr">90</xref>]. The miR-17-92 cluster is associated with downregulation of CTGF and PTEN in GBM stem cells [<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B92" ref-type="bibr">92</xref>]. OncomiR-138 has recently been identified as part of a molecular signature and prognostic biomarker of GSCs [<xref rid="B93" ref-type="bibr">93</xref>]. miR-330, miR-582-5p, and miR-363 promote GSC migration and invasion by reducing apoptosis [<xref rid="B94" ref-type="bibr">94</xref>, <xref rid="B95" ref-type="bibr">95</xref>]. miR-1275 induces GSC proliferation<italic> via</italic> a polycomb mediated silencing mechanism and silencing of Claudin11 protein [<xref rid="B96" ref-type="bibr">96</xref>].</p></sec><sec id="sec8"><title>8. miRNAs in Pediatric Glioma</title><p>Although infrequent in children (about 15% of brain tumors), pediatric high grade gliomas (pHGG) account for high mortality [<xref rid="B97" ref-type="bibr">97</xref>] which depending on the key signaling pathways and copy number [<xref rid="B98" ref-type="bibr">98</xref>] is differentiated from adult high grade gliomas (aHGG). The deregulation of miR-129, miR-142-5p, and miR-25 in pHGG has been reported using four samples [<xref rid="B99" ref-type="bibr">99</xref>]. However, the high throughput microRNA study comparing pHGG, aHGG, and normal brain tissues showed the upregulation of oncogenic miR-17-92 cluster and miR-21 in pHGG [<xref rid="B92" ref-type="bibr">92</xref>]. Moreover, using pHGG cell lines, it was showed that the modulation of proliferation and tumorigenic signaling by miR-17-92 cluster in pHGG was by targeting tumour suppressors like PTEN and RB1.</p><p>All the above findings both in adult and pediatric gliomas suggested that microRNAs in gliomas and GSCs have a potential role in regulating fundamental core stem cell pathways and directing the fate of cancerous tissue to be either benign or malignant. A summary is provided in <xref ref-type="table" rid="tab1">Table 1</xref>.</p></sec><sec id="sec9"><title>9. Medulloblastoma</title><p>Childhood cancers are the leading cause of disease-related mortality in children [<xref rid="B109" ref-type="bibr">100</xref>]. Medulloblastoma (MB) is the most common malignant brain tumour in children [<xref rid="B109" ref-type="bibr">100</xref>]. MB is often associated with disruption or deregulation of cerebellar development could occur in either pre- or postnatal developmental windows. MB is found to arise from cells in the external granular layer (EGL) or the subependymal matrix residing within the cerebellum [<xref rid="B110" ref-type="bibr">101</xref>]. MB has the potential to metastasize along the spinal cord, which portends a worse prognosis [<xref rid="B111" ref-type="bibr">102</xref>]. Current regimens for treatment of MB include a combination of surgery, craniospinal radiotherapy, and chemotherapy. Yet, depending on which of the 4 subgroups (Wnt, Shh, group 3, and group 4) the MB is classified into, the clinical outcome varies [<xref rid="B111" ref-type="bibr">102</xref>]. These four distinct groups are formulated according to the unique molecular characteristics previously described [<xref rid="B110" ref-type="bibr">101</xref>, <xref rid="B112" ref-type="bibr">103</xref>, <xref rid="B113" ref-type="bibr">104</xref>]. Despite the effectiveness of modern cancer therapies, long-term side effects are demonstrated in patients by cognition defects and developmental delays [<xref rid="B114" ref-type="bibr">105</xref>]. Furthermore, tumour recurrence occurs in 20 to 30% of all patients with clinical outcomes that are far worse than they were at primary diagnosis [<xref rid="B115" ref-type="bibr">106</xref>].</p><sec id="sec9.1"><title>9.1. MicroRNAs as Tumor Suppressors in MB</title><p>miRNAs are highly associated with many cancers, and their role has also been described in MB [<xref rid="B116" ref-type="bibr">107</xref>]. Ferretti et al. in 2008 was one among the first to illustrate the characterization of miRNA in [<xref rid="B117" ref-type="bibr">108</xref>]. In their study, miR-125b, miR-324-5p, and miR-326 were demonstrated as the suppressors of sonic hedgehog signaling (Shh) pathway and MB cells showed increased proliferation when these microRNAs were diminished. The same group in 2009 depicted several microRNAs to be involved in regulation of BTICs in MBs [<xref rid="B118" ref-type="bibr">109</xref>]. miR-9 and miR-125 were the most promising as growth-inhibitory and apoptotic microRNAs for BTICs [<xref rid="B118" ref-type="bibr">109</xref>]. Another group in 2008 uncovered the role of miR-124 in MB [<xref rid="B119" ref-type="bibr">110</xref>]. miR-124 shows decreased expression levels in MB cells [<xref rid="B120" ref-type="bibr">111</xref>], with its restoration leading to inhibition of cell proliferation [<xref rid="B119" ref-type="bibr">110</xref>]. miR-124 is normally expressed in external granule cells of the cerebellum, which may represent a cell of origin in MB [<xref rid="B119" ref-type="bibr">110</xref>]. Cyclin dependent kinase 6 (CDK6) [<xref rid="B119" ref-type="bibr">110</xref>] and solute carrier family 16 (SLC16A1) [<xref rid="B120" ref-type="bibr">111</xref>] are the two identified key targets of miR-124 in MB. This suggests that miRNAs may be actively involved in the initiation and maintenance of MB through regulation of cell proliferation and cell cycle.</p><p>Role of miR-218 was also investigated in a Shh-dependent MB cell line. Cells with lower miR-218 levels presented increased tumour-like properties using both<italic> in vitro</italic> and<italic> in vivo</italic> experimental approaches [<xref rid="B123" ref-type="bibr">112</xref>]. Cell migration and invasion declined as miR-218 expression levels increased, suggesting miR-218 functioned as a tumour suppressor. Likewise, miR-199b-5p also functions as a tumour suppressor since overexpression of this miRNA leads to reduced tumour growth in MB [<xref rid="B124" ref-type="bibr">113</xref>]. Other studies further support miR-199b to be responsible for regulating BTICs within MB [<xref rid="B125" ref-type="bibr">114</xref>] by regulating the Notch pathway [<xref rid="B124" ref-type="bibr">113</xref>]. The miR-34 family was found to suppress CD15+/CD133+ BTICs. Similar to GBM, this effect was achieved by targeting the Notch-signaling pathway [<xref rid="B126" ref-type="bibr">115</xref>]. miR-34a overexpression in an<italic> in vitro</italic> study displayed inhibition of cell proliferation and cell invasion while simultaneously enriching chemotherapy sensitivity [<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B127" ref-type="bibr">116</xref>]. Another recent study proved the role of miR-34a deficiency in accelerating MB formation<italic> in vivo</italic> [<xref rid="B128" ref-type="bibr">117</xref>].</p><p>Other studies focusing on Wnt-dependent MB show decreased expression of miR-193 and miR-224 to enhance cell proliferation and decrease radiosensitivity [<xref rid="B133" ref-type="bibr">118</xref>]. A small population of BTICs regulated by these microRNAs not only confers cancer stem cell characteristics in cells but also provides a means of evading therapies [<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B133" ref-type="bibr">118</xref>, <xref rid="B134" ref-type="bibr">119</xref>].</p><p>Some of the microRNAs postulated during normal embryonic and NSC development may also regulate CSCs. One such example is miR-1280. A study demonstrated the appearance of cancer stem cell-like properties in MB cells upon decreasing miR-1280 expression [<xref rid="B135" ref-type="bibr">120</xref>]. Downregulation of miR-1280 leads to increased Jagged-2 that causes metastatic dissemination and poor outcome in MB patients [<xref rid="B135" ref-type="bibr">120</xref>]. Recently, miR-135a is shown to inhibit specifically cancer stem cell driven MB by targeting Arhgef6 (rho guanine nucleotide exchange factor 6), a gene frequently upregulated in MB [<xref rid="B136" ref-type="bibr">121</xref>]. This emphasizes the importance of miRNA mediated targeting of BTICs.</p></sec><sec id="sec9.2"><title>9.2. OncomiRs in MB</title><p>The famous oncomiR cluster miR-17/92 family members, namely, miR-17 and miR-92, were found to be involved in Shh-dependent MB [<xref rid="B121" ref-type="bibr">122</xref>] as both were able to increase the proliferation rates of MB cells when overexpressed [<xref rid="B121" ref-type="bibr">122</xref>, <xref rid="B122" ref-type="bibr">123</xref>]. This polycistronic protooncogene miR-17/92 cluster is amplified in about 6% of pediatric MB [<xref rid="B121" ref-type="bibr">122</xref>]. These miRNAs were shown to either induce or maintain cancer stem cells in MB. This provides evidence of aberrant hedgehog signaling contributing to the pathogenesis of MB both at the level of gene expression and the level of miRNA deregulation.</p><p>Recently miR-21, miR-96, miR-182, miR-183, and miR-142-3p [<xref rid="B118" ref-type="bibr">109</xref>, <xref rid="B129" ref-type="bibr">124</xref>&#x02013;<xref rid="B132" ref-type="bibr">127</xref>] were found to promote tumorigenesis and migration in BTIC of MB. The aforementioned microRNAs function by regulating proliferation, stemness, or escape from therapy. Oncosuppressor miR-128a/b [<xref rid="B118" ref-type="bibr">109</xref>] and oncomiRs miR-17, miR-92 [<xref rid="B121" ref-type="bibr">122</xref>, <xref rid="B122" ref-type="bibr">123</xref>] plays a regulatory role in poor clinical outcome group 3 MB. miR-30b and miR-30d expressions may also be amplified in MB, thereby suggesting these miRNAs as putative oncogenic targets [<xref rid="B137" ref-type="bibr">128</xref>]. A list of microRNAs modulating BTICs in MB is compiled in <xref ref-type="table" rid="tab2">Table 2</xref>. However, it is still unclear whether many of these microRNAs are capable of directly regulating only BTICs or the whole tumour cells in MB as majority of the miRNAs affect both populations.</p></sec></sec><sec id="sec10"><title>10. Craniopharyngioma</title><p>Craniopharyngioma (CP) is a benign tumour of the sellar region that is commonly diagnosed in children. Due to its unpredictable growth pattern, it is often associated with severe adverse neurological effects and significant reduction in quality of life [<xref rid="B138" ref-type="bibr">129</xref>]. Initially it was proposed that CP can originate from either the ectopic remnants of Rathke's Pouch (RP) or embryonal epithelial cells [<xref rid="B139" ref-type="bibr">130</xref>, <xref rid="B140" ref-type="bibr">131</xref>], but the recent development of mouse models reveals a small population of cells in CP that share the properties with stem cells [<xref rid="B141" ref-type="bibr">132</xref>]. Wnt/<italic>&#x003b2;</italic>-catenin pathway overactivation has been shown in these stem cells along with the high levels of secreted mitogenic signals like Shh, BMP, and FGF family. This model has provided first insight into putative CP BTICs [<xref rid="B141" ref-type="bibr">132</xref>]. Further studies have revealed that a fraction of cells with increased <italic>&#x003b2;</italic>-catenin levels have lower expression of Ki67 with long telomeres, both of which are the features of stem cells [<xref rid="B142" ref-type="bibr">133</xref>]. However, it is still unclear whether RP progenitors are truly responsible for CP initiation; therefore, a comprehensive analysis of microRNA signatures of those cells might provide the opportunity to conclusively elucidate the CP BTICs.</p><p>In 2013, Campanini et al. performed comprehensive microRNA expression profiling in CP in order to understand the role of microRNAs in CP tumorigenesis [<xref rid="B143" ref-type="bibr">134</xref>] (<xref ref-type="table" rid="tab3">Table 3</xref>). One of the interesting findings of the paper is that, in tumours harbouring<italic> CTNNB1</italic> mutation, there was downregulation of miR-16 and miR-141. Furthermore,<italic> in silico</italic> analysis demonstrated that miR-23b, miR-24-2, miR-141, and miR-449 act as tumour suppressors by inhibiting translation of<italic> CTNNB1</italic> mRNA, while miR-150 was proposed to be acting as an oncomiR by modulating adenomatous polyposis coli (APC) [<xref rid="B143" ref-type="bibr">134</xref>]. Although there is no direct correlation between BTICs and microRNA profiling for CP in this study, it gives an outline of microRNAs that are postulated in maintenance and signaling of other types of cancer stem cells [<xref rid="B144" ref-type="bibr">135</xref>&#x02013;<xref rid="B146" ref-type="bibr">137</xref>]. Further studies are required to reveal a specific miRNA expression signature that will be used to identify a more proliferative, stem-like, and likely more aggressive case of CP, thereby allowing for discovery of novel therapeutic targets to mark CP BTIC populations.</p></sec><sec id="sec11"><title>11. Ependymoma</title><p>Ependymoma is a common pediatric and adult CNS tumour that is thought to originate from cells lining ventricular spaces and radial glial cells of the brain [<xref rid="B147" ref-type="bibr">138</xref>&#x02013;<xref rid="B149" ref-type="bibr">140</xref>]. Although chemotherapy and radiotherapy comprise the standard regimen for the treatment of these patients, the patient outcome and 5-year survival remain poor due to recurrence [<xref rid="B148" ref-type="bibr">139</xref>, <xref rid="B150" ref-type="bibr">141</xref>]. There is still no biological marker that can be correlated with disease progression and prognosis [<xref rid="B151" ref-type="bibr">142</xref>]. A study by Costa et al. has identified 28 miRNAs (<xref ref-type="table" rid="tab3">Table 3</xref>) that are differentially expressed in ependymoma when compared to normal ependymal cells [<xref rid="B152" ref-type="bibr">143</xref>]. An interesting finding emerging from the study was the identification of underexpressed miR-203 as an independent factor correlating with time to relapse, which ultimately can be used in disease management and prediction of ependymoma progression and recurrence [<xref rid="B152" ref-type="bibr">143</xref>]. Studies in other human cancers revealed the association of miR-203 with solid as well as hematopoietic malignancies. In leukemia, miR-203 has been implicated in the regulation of the<italic> BCR-ABL</italic> gene [<xref rid="B153" ref-type="bibr">144</xref>, <xref rid="B154" ref-type="bibr">145</xref>]. Moreover, in skin, miR-203 is associated with repression of &#x0201c;stemness&#x0201d; [<xref rid="B155" ref-type="bibr">146</xref>]. A multivariate analysis using paraffin-embedded (FFPE) ependymoma samples from patients has identified let-7d, miR-596, and miR-367 to be associated with increased overall survival [<xref rid="B152" ref-type="bibr">143</xref>]. These microRNAs are shown to regulate stem cells in other cancers like breast and brain [<xref rid="B156" ref-type="bibr">147</xref>, <xref rid="B157" ref-type="bibr">148</xref>]. Furthermore, miR-34a was shown to be overexpressed in supratentorial ependymomas which are associated with better prognosis in comparison to infratentorial tumours [<xref rid="B152" ref-type="bibr">143</xref>]. A signature of 5 miRNAs (miR-376a, miR-381, miR-411, miR-432, and miR-487) along with miR-203 that can be mapped to both chromosome 14q32.1 and 14q32.33 is shown in ependymoma and other tumours to be regulated by DNA methylation, proving the global dysregulation of this chromosome in carcinomas [<xref rid="B152" ref-type="bibr">143</xref>, <xref rid="B158" ref-type="bibr">149</xref>, <xref rid="B159" ref-type="bibr">150</xref>]. Furthermore, a recent work published the role of miR-376a in the regulation of human dental stem cells [<xref rid="B160" ref-type="bibr">151</xref>]. This further emphasized a common mode of deregulation of microRNAs in stem cells and multiple cancer types that may be affecting only a small cell population which originate these tumours.</p></sec><sec id="sec12"><title>12. Atypical Teratoid/Rhabdoid Tumours</title><p>Atypical teratoid/rhabdoid tumours (AT/RT) are highly aggressive tumours characterized by biallelic inactivation of the<italic> SMARCB1/INI-1/hSNF5/BAF47</italic> tumour suppressor gene [<xref rid="B161" ref-type="bibr">152</xref>, <xref rid="B162" ref-type="bibr">153</xref>]. Whole exome sequencing of AT/RT tissues performed by Zhang et al. has identified a copy number decrease of the genomic locus containing<italic> let-7a3</italic> and<italic> let-7b</italic> microRNAs as well as overexpression of<italic> HMGA2</italic> [<xref rid="B163" ref-type="bibr">154</xref>]. They further showed that HMGA2 overexpression in AT/RT samples was not associated with the loss of SMARCB1. Similar to other human cancers [<xref rid="B164" ref-type="bibr">155</xref>, <xref rid="B165" ref-type="bibr">156</xref>], the<italic> let-7</italic> family negatively regulates the<italic> HMGA2</italic> oncogene in AT/RT as well [<xref rid="B163" ref-type="bibr">154</xref>]. Interestingly, both overexpression of let-7a3 and let-7b and knockdown of HMGA2 resulted in decreased cell proliferation and colony formation in a rhabdoid tumour cell line [<xref rid="B163" ref-type="bibr">154</xref>], emphasizing the role of these microRNAs in cells selected under stem cell conditions. Although the regulation of HMGA2 by let-7 miRNAs is not unique to AT/RT and has been previously discussed in breast [<xref rid="B166" ref-type="bibr">157</xref>], lung [<xref rid="B167" ref-type="bibr">158</xref>], and ovarian [<xref rid="B168" ref-type="bibr">159</xref>] cancers, it provides a new therapeutic avenue in management of AT/RT tumours.</p><p>Both the aggressive nature and heterogeneity of AT/RT can suggest the existence of BTIC population responsible for tumour initiation and growth [<xref rid="B169" ref-type="bibr">160</xref>&#x02013;<xref rid="B171" ref-type="bibr">162</xref>]. A fraction of cells expressing stem cell marker CD133 was shown to have an increased expression of several developmental genes including Oct 4, Sox2, Nestin, and Bmi1 [<xref rid="B172" ref-type="bibr">163</xref>&#x02013;<xref rid="B174" ref-type="bibr">165</xref>]. Although several gene expression studies have been conducted in attempt to further characterize AT/RT BTICs, there is still a need for development of<italic> in vivo</italic> models that will help in functionally evaluating the putative BTICs and the microRNAs deregulated in them.</p></sec><sec id="sec13"><title>13. Pituitary Adenoma and Pilocytic Astrocytoma</title><p>Pituitary adenomas are benign tumours that account for 10&#x02013;15% of all diagnosed brain malignancies [<xref rid="B175" ref-type="bibr">166</xref>]. The cell of origin for pituitary tumours can be one of the five differentiated cell types: growth hormone- (GH-) secreting, adrenocorticotrophic hormone- (ACTH-) secreting, prolactin- (PRL-) secreting, thyroid-stimulating hormone- (TSH-) secreting, or nonfunctioning pituitary cells (NFA) within the pituitary gland [<xref rid="B176" ref-type="bibr">167</xref>]. The majority of pituitary adenomas are indolent, some pituitary tumours are associated with fast growth and even metastasis to distant site such as lymph nodes and liver [<xref rid="B175" ref-type="bibr">166</xref>]. Although recent studies demonstrated deregulated expression of several miRNAs in the pituitary adenomas, their function and target genes remain largely unknown. A likely difference between slow growing and fast growing tumours is cell cycle regulation. Several miRNAs have been reported to regulate the cell cycle in the pituitary adenomas. As mentioned in BTICs of MB and GBM, miR-128 is also downregulated in pituitary adenomas [<xref rid="B177" ref-type="bibr">168</xref>]. Important cell cycle regulatory proteins such as PTEN and Bmi1 are regulated by miR-26b and miR-128, respectively [<xref rid="B177" ref-type="bibr">168</xref>]. miR-128a and miR-155 were found to be overexpressed in GH and NFA which resulted in the downregulation of Wee1, a known cell cycle inhibitor [<xref rid="B178" ref-type="bibr">169</xref>, <xref rid="B179" ref-type="bibr">170</xref>]. This dual nature of miR-128 family with its different members playing both oncogenic and tumour suppressor activities can be explained based on the microRNAs processing from pri-miR to pre-miR to the export in cytoplasm [<xref rid="B180" ref-type="bibr">171</xref>]. Three major mechanisms suggest the differential action of miR-128 in different cell types. They are point mutation/single nucleotide polymorphism [<xref rid="B181" ref-type="bibr">172</xref>], loss of heterozygosity (LOH) or amplification in miR-128 host gene ARPP21 [<xref rid="B182" ref-type="bibr">173</xref>], and epigenetic alteration of miR-128 gene by CpG-island methylation in promoter regions [<xref rid="B44" ref-type="bibr">44</xref>]. Be it any mechanism, the aberrant expression of miR-128 family members needs further study to clarify its role in tumorigenesis and cancer progression [<xref rid="B183" ref-type="bibr">174</xref>, <xref rid="B184" ref-type="bibr">175</xref>].</p><p>In addition to deregulation of cell cycle, an important hallmark of cancer is the ability of cells to evade apoptosis. miR-212 is shown to be strongly upregulated in pituitary tumours [<xref rid="B185" ref-type="bibr">176</xref>] and a study suggested death effector domain-containing protein (DEDD) as its potential target. This is a protein involved in apoptosis signaling [<xref rid="B186" ref-type="bibr">177</xref>]. Despite rare cases of metastasis of pituitary tumours, there are reports linking miRNA deregulation to tumour invasion and metastasis [<xref rid="B187" ref-type="bibr">178</xref>, <xref rid="B188" ref-type="bibr">179</xref>]. Pituitary tumour transforming gene (PTTG) protein 1 is associated with increased tumour invasiveness [<xref rid="B187" ref-type="bibr">178</xref>] and is targeted by miR-126 and miR-381. These two microRNAs are downregulated in GH-secreting pituitary adenomas [<xref rid="B188" ref-type="bibr">179</xref>]. Furthermore, the differential expression of miRNAs is not uniform among all types of pituitary malignancies. For example, overexpression of miR-23a, miR-23b, and miR-24-2 and downregulation of miR-26b are common to GH-secreting and PRL-secreting pituitaries but are not observed in nonfunctioning adenomas [<xref rid="B185" ref-type="bibr">176</xref>].</p><p>Similar to pituitary adenomas, miRNA deregulation in pilocytic astrocytoma was shown to correlate with increased proliferation, migration, and evasion of apoptosis [<xref rid="B99" ref-type="bibr">99</xref>]. A study by Zhi et al. in 2014 demonstrated the association of miR-181b-5p downregulation with poor prognosis [<xref rid="B189" ref-type="bibr">180</xref>]. Increased tumor initiating cell properties were attributed to upregulated expression of neurooncological ventral antigen 1 (NOVA 1) that is normally regulated by miR-181b-5p [<xref rid="B189" ref-type="bibr">180</xref>], further emphasizing the role of targeting BTICs for complete eradication of cancer.</p></sec><sec id="sec14"><title>14. MicroRNAs: Therapeutic Applications</title><p>Treatment of cancer may eventually necessitate a multimodal approach of traditional chemotherapy/radiotherapy regimens and nontraditional RNA-based approaches. MicroRNA/RNAi based therapeutics have the potential to overcome the ineffectiveness of current treatments by either silencing the oncogenes or blocking genes that cause downregulation of oncosuppressors. This kind of novel treatment requires the discovery and complete elucidation of the functional biology of microRNAs and effective targeted delivery to their molecular targets in cancer initiating and maintaining cells. The next critical step is to gain an understanding of microRNA profiling for cancerous versus healthy cells and corresponding functional analyses. Delivery to the CNS poses another big challenge due to the difficulties in crossing the blood brain barrier and other extracellular matrix components [<xref rid="B193" ref-type="bibr">181</xref>]. Nevertheless, this caveat can be overcome using strategies such as nanoparticles and liposomes as encapsulated carriers [<xref rid="B194" ref-type="bibr">182</xref>]. Another method could be to directly target therapies in brain tumour cells using viral delivery approaches [<xref rid="B193" ref-type="bibr">181</xref>]. Convection-enhanced delivery can be used postsurgically to deliver RNA molecules to the tumour bed [<xref rid="B195" ref-type="bibr">183</xref>].</p><p>In conclusion, further developments for microRNA-mediated therapy are needed to provide clinicians with another avenue in treating the patients with deadly brain tumours. This will involve challenges in ensuring the stability and delivery of RNA therapeutics in<italic> in vivo</italic> systems and further depending on extent of the disease miRNAs can be used in conjunction with other available therapies.</p></sec></body><back><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declare that there is no conflict of interests regarding the publication of this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartel</surname><given-names>D. P.</given-names></name><name><surname>Chen</surname><given-names>C.-Z.</given-names></name></person-group><article-title>Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs</article-title><source><italic>Nature Reviews Genetics</italic></source><year>2004</year><volume>5</volume><issue>5</issue><fpage>396</fpage><lpage>400</lpage><pub-id pub-id-type="other">2-s2.0-1942435249</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>H. R.</given-names></name><name><surname>Schoenfeld</surname><given-names>L. W.</given-names></name><name><surname>Ruby</surname><given-names>J. G.</given-names></name><etal/></person-group><article-title>Mammalian microRNAs: experimental evaluation of novel and previously annotated genes</article-title><source><italic>Genes &#x00026; Development</italic></source><year>2010</year><volume>24</volume><issue>10</issue><fpage>992</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1101/gad.1884710</pub-id><pub-id pub-id-type="other">2-s2.0-77952368550</pub-id><pub-id pub-id-type="pmid">20413612</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasudevan</surname><given-names>S.</given-names></name><name><surname>Tong</surname><given-names>Y.</given-names></name><name><surname>Steitz</surname><given-names>J. A.</given-names></name></person-group><article-title>Switching from repression to activation: microRNAs can up-regulate translation</article-title><source><italic>Science</italic></source><year>2007</year><volume>318</volume><issue>5858</issue><fpage>1931</fpage><lpage>1934</lpage><pub-id pub-id-type="doi">10.1126/science.1149460</pub-id><pub-id pub-id-type="other">2-s2.0-36749026906</pub-id><pub-id pub-id-type="pmid">18048652</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Vasudevan</surname><given-names>S.</given-names></name></person-group><article-title>Post-transcriptional stimulation of gene expression by MicroRNAs</article-title><source><italic>Advances in Experimental Medicine and Biology</italic></source><year>2013</year><volume>768</volume><fpage>97</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1007/978-1-4614-5107-5-76</pub-id><pub-id pub-id-type="other">2-s2.0-84873532166</pub-id><pub-id pub-id-type="pmid">23224967</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lund</surname><given-names>E.</given-names></name><name><surname>G&#x000fc;ttinger</surname><given-names>S.</given-names></name><name><surname>Calado</surname><given-names>A.</given-names></name><name><surname>Dahlberg</surname><given-names>J. E.</given-names></name><name><surname>Kutay</surname><given-names>U.</given-names></name></person-group><article-title>Nuclear export of microRNA precursors</article-title><source><italic>Science</italic></source><year>2004</year><volume>303</volume><issue>5654</issue><fpage>95</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1126/science.1090599</pub-id><pub-id pub-id-type="other">2-s2.0-0347988235</pub-id><pub-id pub-id-type="pmid">14631048</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Wynsberghe</surname><given-names>P. M.</given-names></name><name><surname>Chan</surname><given-names>S.-P.</given-names></name><name><surname>Slack</surname><given-names>F. J.</given-names></name><name><surname>Pasquinelli</surname><given-names>A. E.</given-names></name></person-group><article-title>Analysis of microRNA expression and function</article-title><source><italic>Methods in Cell Biology</italic></source><year>2011</year><volume>106</volume><fpage>219</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/b978-0-12-544172-8.00008-6</pub-id><pub-id pub-id-type="other">2-s2.0-82355164333</pub-id><pub-id pub-id-type="pmid">22118279</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diederichs</surname><given-names>S.</given-names></name><name><surname>Haber</surname><given-names>D. A.</given-names></name></person-group><article-title>Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression</article-title><source><italic>Cell</italic></source><year>2007</year><volume>131</volume><issue>6</issue><fpage>1097</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.10.032</pub-id><pub-id pub-id-type="other">2-s2.0-36849048778</pub-id><pub-id pub-id-type="pmid">18083100</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>B. P.</given-names></name><name><surname>Burge</surname><given-names>C. B.</given-names></name><name><surname>Bartel</surname><given-names>D. P.</given-names></name></person-group><article-title>Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets</article-title><source><italic>Cell</italic></source><year>2005</year><volume>120</volume><issue>1</issue><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.12.035</pub-id><pub-id pub-id-type="other">2-s2.0-11844278458</pub-id><pub-id pub-id-type="pmid">15652477</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaur</surname><given-names>A.</given-names></name><name><surname>Jewell</surname><given-names>D. A.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Characterization of microRNA expression levels and their biological correlates in human cancer cell lines</article-title><source><italic>Cancer Research</italic></source><year>2007</year><volume>67</volume><issue>6</issue><fpage>2456</fpage><lpage>2468</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-2698</pub-id><pub-id pub-id-type="other">2-s2.0-34047270440</pub-id><pub-id pub-id-type="pmid">17363563</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>B. M.</given-names></name><name><surname>Robles</surname><given-names>A. I.</given-names></name><name><surname>Harris</surname><given-names>C. C.</given-names></name></person-group><article-title>Genetic variation in microRNA networks: the implications for cancer research</article-title><source><italic>Nature Reviews Cancer</italic></source><year>2010</year><volume>10</volume><issue>6</issue><fpage>389</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1038/nrc2867</pub-id><pub-id pub-id-type="other">2-s2.0-77952918274</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calin</surname><given-names>G. A.</given-names></name><name><surname>Sevignani</surname><given-names>C.</given-names></name><name><surname>Dumitru</surname><given-names>C. D.</given-names></name><etal/></person-group><article-title>Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2004</year><volume>101</volume><issue>9</issue><fpage>2999</fpage><lpage>3004</lpage><pub-id pub-id-type="doi">10.1073/pnas.0307323101</pub-id><pub-id pub-id-type="other">2-s2.0-12144290519</pub-id><pub-id pub-id-type="pmid">14973191</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piriyapongsa</surname><given-names>J.</given-names></name><name><surname>Jordan</surname><given-names>I. K.</given-names></name><name><surname>Conley</surname><given-names>A. B.</given-names></name><name><surname>Ronan</surname><given-names>T.</given-names></name><name><surname>Smalheiser</surname><given-names>N. R.</given-names></name></person-group><article-title>Transcription factor binding sites are highly enriched within microRNA precursor sequences</article-title><source><italic>Biology Direct</italic></source><year>2011</year><volume>6, article 61</volume><pub-id pub-id-type="doi">10.1186/1745-6150-6-61</pub-id><pub-id pub-id-type="other">2-s2.0-82455188317</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>B. N.</given-names></name><name><surname>Hilyard</surname><given-names>A. C.</given-names></name><name><surname>Nguyen</surname><given-names>P. H.</given-names></name><name><surname>Lagna</surname><given-names>G.</given-names></name><name><surname>Hata</surname><given-names>A.</given-names></name></person-group><article-title>Smad proteins bind a conserved RNA sequence to promote MicroRNA maturation by Drosha</article-title><source><italic>Molecular Cell</italic></source><year>2010</year><volume>39</volume><issue>3</issue><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.07.011</pub-id><pub-id pub-id-type="other">2-s2.0-77955484492</pub-id><pub-id pub-id-type="pmid">20705240</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Lim</surname><given-names>L. P.</given-names></name><etal/></person-group><article-title>A microRNA component of the p53 tumour suppressor network</article-title><source><italic>Nature</italic></source><year>2007</year><volume>447</volume><issue>7148</issue><fpage>1130</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1038/nature05939</pub-id><pub-id pub-id-type="other">2-s2.0-34250851115</pub-id><pub-id pub-id-type="pmid">17554337</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sylvestre</surname><given-names>Y.</given-names></name><name><surname>de Guire</surname><given-names>V.</given-names></name><name><surname>Querido</surname><given-names>E.</given-names></name><etal/></person-group><article-title>An E2F/miR-20a autoregulatory feedback loop</article-title><source><italic>Journal of Biological Chemistry</italic></source><year>2007</year><volume>282</volume><issue>4</issue><fpage>2135</fpage><lpage>2143</lpage><pub-id pub-id-type="doi">10.1074/jbc.m608939200</pub-id><pub-id pub-id-type="other">2-s2.0-34047267329</pub-id><pub-id pub-id-type="pmid">17135249</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dews</surname><given-names>M.</given-names></name><name><surname>Homayouni</surname><given-names>A.</given-names></name><name><surname>Yu</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster</article-title><source><italic>Nature Genetics</italic></source><year>2006</year><volume>38</volume><issue>9</issue><fpage>1060</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1038/ng1855</pub-id><pub-id pub-id-type="other">2-s2.0-33748302836</pub-id><pub-id pub-id-type="pmid">16878133</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lujambio</surname><given-names>A.</given-names></name><name><surname>Ropero</surname><given-names>S.</given-names></name><name><surname>Ballestar</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Genetic unmasking of an epigenetically silenced microRNA in human cancer cells</article-title><source><italic>Cancer Research</italic></source><year>2007</year><volume>67</volume><issue>4</issue><fpage>1424</fpage><lpage>1429</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-4218</pub-id><pub-id pub-id-type="other">2-s2.0-33847763576</pub-id><pub-id pub-id-type="pmid">17308079</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>J. M.</given-names></name><name><surname>Newman</surname><given-names>M.</given-names></name><name><surname>Parker</surname><given-names>J. S.</given-names></name><name><surname>Morin-Kensicki</surname><given-names>E. M.</given-names></name><name><surname>Wright</surname><given-names>T.</given-names></name><name><surname>Hammond</surname><given-names>S. M.</given-names></name></person-group><article-title>Extensive post-transcriptional regulation of microRNAs and its implications for cancer</article-title><source><italic>Genes and Development</italic></source><year>2006</year><volume>20</volume><issue>16</issue><fpage>2202</fpage><lpage>2207</lpage><pub-id pub-id-type="doi">10.1101/gad.1444406</pub-id><pub-id pub-id-type="other">2-s2.0-33747334621</pub-id><pub-id pub-id-type="pmid">16882971</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D.</given-names></name><name><surname>Weinberg</surname><given-names>R. A.</given-names></name></person-group><article-title>Hallmarks of cancer: the next generation</article-title><source><italic>Cell</italic></source><year>2011</year><volume>144</volume><issue>5</issue><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="other">2-s2.0-79952284127</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>C. E.</given-names></name><name><surname>Kuo</surname><given-names>P. C.</given-names></name></person-group><article-title>The tumor microenvironment</article-title><source><italic>Surgical Oncology</italic></source><year>2012</year><volume>21</volume><issue>3</issue><fpage>172</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.suronc.2011.09.001</pub-id><pub-id pub-id-type="other">2-s2.0-84864708409</pub-id><pub-id pub-id-type="pmid">21963199</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dou</surname><given-names>J.</given-names></name><name><surname>Gu</surname><given-names>N.</given-names></name></person-group><article-title>Emerging strategies for the identification and targeting of cancer stem cells</article-title><source><italic>Tumor Biology</italic></source><year>2010</year><volume>31</volume><issue>4</issue><fpage>243</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1007/s13277-010-0023-y</pub-id><pub-id pub-id-type="other">2-s2.0-77954646313</pub-id><pub-id pub-id-type="pmid">20336402</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wicha</surname><given-names>M. S.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Dontu</surname><given-names>G.</given-names></name></person-group><article-title>Cancer stem cells: an old idea&#x02014;a paradigm shift</article-title><source><italic>Cancer Research</italic></source><year>2006</year><volume>66</volume><issue>4</issue><fpage>1883</fpage><lpage>1890</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.can-05-3153</pub-id><pub-id pub-id-type="other">2-s2.0-33644560281</pub-id><pub-id pub-id-type="pmid">16488983</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnet</surname><given-names>D.</given-names></name><name><surname>Dick</surname><given-names>J. E.</given-names></name></person-group><article-title>Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell</article-title><source><italic>Nature Medicine</italic></source><year>1997</year><volume>3</volume><issue>7</issue><fpage>730</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1038/nm0797-730</pub-id><pub-id pub-id-type="other">2-s2.0-0030789242</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Hajj</surname><given-names>M.</given-names></name><name><surname>Wicha</surname><given-names>M. S.</given-names></name><name><surname>Benito-Hernandez</surname><given-names>A.</given-names></name><name><surname>Morrison</surname><given-names>S. J.</given-names></name><name><surname>Clarke</surname><given-names>M. F.</given-names></name></person-group><article-title>Prospective identification of tumorigenic breast cancer cells</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2003</year><volume>100</volume><issue>7</issue><fpage>3983</fpage><lpage>3988</lpage><pub-id pub-id-type="doi">10.1073/pnas.0530291100</pub-id><pub-id pub-id-type="other">2-s2.0-0037388204</pub-id><pub-id pub-id-type="pmid">12629218</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S. K.</given-names></name><name><surname>Hawkins</surname><given-names>C.</given-names></name><name><surname>Clarke</surname><given-names>I. D.</given-names></name><etal/></person-group><article-title>Identification of human brain tumour initiating cells</article-title><source><italic>Nature</italic></source><year>2004</year><volume>432</volume><issue>7015</issue><fpage>396</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1038/nature03128</pub-id><pub-id pub-id-type="other">2-s2.0-9244241576</pub-id><pub-id pub-id-type="pmid">15549107</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>McLendon</surname><given-names>R. E.</given-names></name><etal/></person-group><article-title>Glioma stem cells promote radioresistance by preferential activation of the DNA damage response</article-title><source><italic>Nature</italic></source><year>2006</year><volume>444</volume><issue>7120</issue><fpage>756</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1038/nature05236</pub-id><pub-id pub-id-type="other">2-s2.0-33845317573</pub-id><pub-id pub-id-type="pmid">17051156</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S. K.</given-names></name><name><surname>Clarke</surname><given-names>I. D.</given-names></name><name><surname>Hide</surname><given-names>T.</given-names></name><name><surname>Dirks</surname><given-names>P. B.</given-names></name></person-group><article-title>Cancer stem cells in nervous system tumors</article-title><source><italic>Oncogene</italic></source><year>2004</year><volume>23</volume><issue>43</issue><fpage>7267</fpage><lpage>7273</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207946</pub-id><pub-id pub-id-type="other">2-s2.0-6044221204</pub-id><pub-id pub-id-type="pmid">15378086</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galli</surname><given-names>R.</given-names></name><name><surname>Binda</surname><given-names>E.</given-names></name><name><surname>Orfanelli</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma</article-title><source><italic>Cancer Research</italic></source><year>2004</year><volume>64</volume><issue>19</issue><fpage>7011</fpage><lpage>7021</lpage><pub-id pub-id-type="pmid">15466194</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemmati</surname><given-names>H. D.</given-names></name><name><surname>Nakano</surname><given-names>I.</given-names></name><name><surname>Lazareff</surname><given-names>J. A.</given-names></name><etal/></person-group><article-title>Cancerous stem cells can arise from pediatric brain tumors</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2003</year><volume>100</volume><issue>25</issue><fpage>15178</fpage><lpage>15183</lpage><pub-id pub-id-type="doi">10.1073/pnas.2036535100</pub-id><pub-id pub-id-type="other">2-s2.0-0344735881</pub-id><pub-id pub-id-type="pmid">14645703</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capela</surname><given-names>A.</given-names></name><name><surname>Temple</surname><given-names>S.</given-names></name></person-group><article-title>LeX/ssea-1 is expressed by adult mouse CNS stem cells, identifying them as nonependymal</article-title><source><italic>Neuron</italic></source><year>2002</year><volume>35</volume><issue>5</issue><fpage>865</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(02)00835-8</pub-id><pub-id pub-id-type="other">2-s2.0-0037194887</pub-id><pub-id pub-id-type="pmid">12372282</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Read</surname><given-names>T.-A.</given-names></name><name><surname>Fogarty</surname><given-names>M. P.</given-names></name><name><surname>Markant</surname><given-names>S. L.</given-names></name><etal/></person-group><article-title>Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma</article-title><source><italic>Cancer Cell</italic></source><year>2009</year><volume>15</volume><issue>2</issue><fpage>135</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.12.016</pub-id><pub-id pub-id-type="other">2-s2.0-58649111264</pub-id><pub-id pub-id-type="pmid">19185848</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Son</surname><given-names>M. J.</given-names></name><name><surname>Woolard</surname><given-names>K.</given-names></name><name><surname>Nam</surname><given-names>D.-H.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Fine</surname><given-names>H. A.</given-names></name></person-group><article-title>SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma</article-title><source><italic>Cell Stem Cell</italic></source><year>2009</year><volume>4</volume><issue>5</issue><fpage>440</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2009.03.003</pub-id><pub-id pub-id-type="other">2-s2.0-65349115320</pub-id><pub-id pub-id-type="pmid">19427293</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karsten</surname><given-names>U.</given-names></name><name><surname>Goletz</surname><given-names>S.</given-names></name></person-group><article-title>What makes cancer stem cell markers different?</article-title><source><italic>SpringerPlus</italic></source><year>2013</year><volume>2</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1186/2193-1801-2-301</pub-id><pub-id pub-id-type="other">2-s2.0-84881247532</pub-id><pub-id pub-id-type="pmid">23419944</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdouh</surname><given-names>M.</given-names></name><name><surname>Facchino</surname><given-names>S.</given-names></name><name><surname>Chatoo</surname><given-names>W.</given-names></name><name><surname>Balasingam</surname><given-names>V.</given-names></name><name><surname>Ferreira</surname><given-names>J.</given-names></name><name><surname>Bernier</surname><given-names>G.</given-names></name></person-group><article-title>BMI1 sustains human glioblastoma multiforme stem cell renewal</article-title><source><italic>The Journal of Neuroscience</italic></source><year>2009</year><volume>29</volume><issue>28</issue><fpage>8884</fpage><lpage>8896</lpage><pub-id pub-id-type="doi">10.1523/jneurosci.0968-09.2009</pub-id><pub-id pub-id-type="other">2-s2.0-67650727135</pub-id><pub-id pub-id-type="pmid">19605626</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verginelli</surname><given-names>F.</given-names></name><name><surname>Perin</surname><given-names>A.</given-names></name><name><surname>Dali</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Transcription factors FOXG1 and Groucho/TLE promote glioblastoma growth</article-title><source><italic>Nature Communications</italic></source><year>2013</year><volume>4, article 2956</volume><pub-id pub-id-type="doi">10.1038/ncomms3956</pub-id><pub-id pub-id-type="other">2-s2.0-84890943320</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bexell</surname><given-names>D.</given-names></name><name><surname>Gunnarsson</surname><given-names>S.</given-names></name><name><surname>Siesj&#x000f6;</surname><given-names>P.</given-names></name><name><surname>Bengzon</surname><given-names>J.</given-names></name><name><surname>Darabi</surname><given-names>A.</given-names></name></person-group><article-title>CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas</article-title><source><italic>International Journal of Cancer</italic></source><year>2009</year><volume>125</volume><issue>1</issue><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1002/ijc.24306</pub-id><pub-id pub-id-type="other">2-s2.0-66149130683</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velpula</surname><given-names>K. K.</given-names></name><name><surname>Dasari</surname><given-names>V. R.</given-names></name><name><surname>Tsung</surname><given-names>A. J.</given-names></name><name><surname>Dinh</surname><given-names>D. H.</given-names></name><name><surname>Rao</surname><given-names>J. S.</given-names></name></person-group><article-title>Cord blood stem cells revert glioma stem cell EMT by down regulating transcriptional activation of Sox2 and Twist1</article-title><source><italic>Oncotarget</italic></source><year>2011</year><volume>2</volume><issue>12</issue><fpage>1028</fpage><lpage>1042</lpage><pub-id pub-id-type="other">2-s2.0-84862008052</pub-id><pub-id pub-id-type="pmid">22184289</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodini</surname><given-names>C. O.</given-names></name><name><surname>Suzuki</surname><given-names>D. E.</given-names></name><name><surname>Saba-Silva</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Expression analysis of stem cell-related genes reveal OCT4 as a predictor of poor clinical outcome in medulloblastoma</article-title><source><italic>Journal of Neuro-Oncology</italic></source><year>2012</year><volume>106</volume><issue>1</issue><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1007/s11060-011-0647-9</pub-id><pub-id pub-id-type="other">2-s2.0-83055194662</pub-id><pub-id pub-id-type="pmid">21725800</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitsui</surname><given-names>K.</given-names></name><name><surname>Tokuzawa</surname><given-names>Y.</given-names></name><name><surname>Itoh</surname><given-names>H.</given-names></name><etal/></person-group><article-title>The homeoprotein nanog is required for maintenance of pluripotency in mouse epiblast and ES cells</article-title><source><italic>Cell</italic></source><year>2003</year><volume>113</volume><issue>5</issue><fpage>631</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(03)00393-3</pub-id><pub-id pub-id-type="other">2-s2.0-0037806031</pub-id><pub-id pub-id-type="pmid">12787504</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>N.</given-names></name><name><surname>Po</surname><given-names>A.</given-names></name><name><surname>Miele</surname><given-names>E.</given-names></name><etal/></person-group><article-title>MicroRNA-17-92 cluster is a direct Nanog target and controls neural stem cell through Trp53inp1</article-title><source><italic>The EMBO Journal</italic></source><year>2013</year><volume>32</volume><issue>21</issue><fpage>2819</fpage><lpage>2832</lpage><pub-id pub-id-type="doi">10.1038/emboj.2013.214</pub-id><pub-id pub-id-type="other">2-s2.0-84887046837</pub-id><pub-id pub-id-type="pmid">24076654</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Po</surname><given-names>A.</given-names></name><name><surname>Ferretti</surname><given-names>E.</given-names></name><name><surname>Miele</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Hedgehog controls neural stem cells through p53-independent regulation of Nanog</article-title><source><italic>The EMBO Journal</italic></source><year>2010</year><volume>29</volume><issue>15</issue><fpage>2646</fpage><lpage>2658</lpage><pub-id pub-id-type="doi">10.1038/emboj.2010.131</pub-id><pub-id pub-id-type="other">2-s2.0-77955362243</pub-id><pub-id pub-id-type="pmid">20581804</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zbinden</surname><given-names>M.</given-names></name><name><surname>Duquet</surname><given-names>A.</given-names></name><name><surname>Lorente-Trigos</surname><given-names>A.</given-names></name><name><surname>Ngwabyt</surname><given-names>S.-N.</given-names></name><name><surname>Borges</surname><given-names>I.</given-names></name><name><surname>Ruiz I. Altaba</surname><given-names>A.</given-names></name></person-group><article-title>NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53</article-title><source><italic>EMBO Journal</italic></source><year>2010</year><volume>29</volume><issue>15</issue><fpage>2659</fpage><lpage>2674</lpage><pub-id pub-id-type="doi">10.1038/emboj.2010.137</pub-id><pub-id pub-id-type="other">2-s2.0-77955428416</pub-id><pub-id pub-id-type="pmid">20581802</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douville</surname><given-names>J.</given-names></name><name><surname>Beaulieu</surname><given-names>R.</given-names></name><name><surname>Balicki</surname><given-names>D.</given-names></name></person-group><article-title>ALDH1 as a functional marker of cancer stem and progenitor cells</article-title><source><italic>Stem Cells and Development</italic></source><year>2009</year><volume>18</volume><issue>1</issue><fpage>17</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1089/scd.2008.0055</pub-id><pub-id pub-id-type="other">2-s2.0-60149101077</pub-id><pub-id pub-id-type="pmid">18573038</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stacy</surname><given-names>A. E.</given-names></name><name><surname>Jansson</surname><given-names>P. J.</given-names></name><name><surname>Richardson</surname><given-names>D. R.</given-names></name></person-group><article-title>Molecular pharmacology of ABCG2 and its role in chemoresistance</article-title><source><italic>Molecular Pharmacology</italic></source><year>2013</year><volume>84</volume><issue>5</issue><fpage>655</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1124/mol.113.088609</pub-id><pub-id pub-id-type="other">2-s2.0-84885972386</pub-id><pub-id pub-id-type="pmid">24021215</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varela</surname><given-names>M. A.</given-names></name><name><surname>Roberts</surname><given-names>T. C.</given-names></name><name><surname>Wood</surname><given-names>M. J. A.</given-names></name></person-group><article-title>Epigenetics and ncRNAs in brain function and disease: mechanisms and prospects for therapy</article-title><source><italic>Neurotherapeutics</italic></source><year>2013</year><volume>10</volume><issue>4</issue><fpage>621</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1007/s13311-013-0212-7</pub-id><pub-id pub-id-type="other">2-s2.0-84886255734</pub-id><pub-id pub-id-type="pmid">24068583</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gladson</surname><given-names>C. L.</given-names></name><name><surname>Prayson</surname><given-names>R. A.</given-names></name><name><surname>Liu</surname><given-names>W. M.</given-names></name></person-group><article-title>The pathobiology of glioma tumors</article-title><source><italic>Annual Review of Pathology: Mechanisms of Disease</italic></source><year>2010</year><volume>5</volume><fpage>33</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-121808-102109</pub-id><pub-id pub-id-type="other">2-s2.0-77949883876</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohler</surname><given-names>B. A.</given-names></name><name><surname>Ward</surname><given-names>E.</given-names></name><name><surname>McCarthy</surname><given-names>B. J.</given-names></name><etal/></person-group><article-title>Annual report to the nation on the status of cancer, 1975&#x02013;2007, featuring tumors of the brain and other nervous system</article-title><source><italic>Journal of the National Cancer Institute</italic></source><year>2011</year><volume>103</volume><issue>9</issue><fpage>714</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1093/jnci/djr077</pub-id><pub-id pub-id-type="other">2-s2.0-79955768010</pub-id><pub-id pub-id-type="pmid">21454908</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R.</given-names></name><name><surname>Hegi</surname><given-names>M. E.</given-names></name><name><surname>Mason</surname><given-names>W. P.</given-names></name><etal/></person-group><article-title>Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial</article-title><source><italic>The Lancet Oncology</italic></source><year>2009</year><volume>10</volume><issue>5</issue><fpage>459</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(09)70025-7</pub-id><pub-id pub-id-type="pmid">19269895</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignatova</surname><given-names>T. N.</given-names></name><name><surname>Kukekov</surname><given-names>V. G.</given-names></name><name><surname>Laywell</surname><given-names>E. D.</given-names></name><name><surname>Suslov</surname><given-names>O. N.</given-names></name><name><surname>Vrionis</surname><given-names>F. D.</given-names></name><name><surname>Steindler</surname><given-names>D. A.</given-names></name></person-group><article-title>Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro</article-title><source><italic>Glia</italic></source><year>2002</year><volume>39</volume><issue>3</issue><fpage>193</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1002/glia.10094</pub-id><pub-id pub-id-type="other">2-s2.0-0036737914</pub-id><pub-id pub-id-type="pmid">12203386</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabatabai</surname><given-names>G.</given-names></name><name><surname>Weller</surname><given-names>M.</given-names></name></person-group><article-title>Glioblastoma stem cells</article-title><source><italic>Cell and Tissue Research</italic></source><year>2011</year><volume>343</volume><issue>3</issue><fpage>459</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1007/s00441-010-1123-0</pub-id><pub-id pub-id-type="other">2-s2.0-79953813644</pub-id><pub-id pub-id-type="pmid">21253762</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Sage</surname><given-names>J. C.</given-names></name><name><surname>Miller</surname><given-names>M. R.</given-names></name><etal/></person-group><article-title>Mosaic analysis with double markers reveals tumor cell of origin in glioma</article-title><source><italic>Cell</italic></source><year>2011</year><volume>146</volume><issue>2</issue><fpage>209</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.06.014</pub-id><pub-id pub-id-type="other">2-s2.0-79960809488</pub-id><pub-id pub-id-type="pmid">21737130</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>C.</given-names></name><name><surname>Zaiden</surname><given-names>N.</given-names></name><name><surname>Chong</surname><given-names>K.-H.</given-names></name><etal/></person-group><article-title>Characterization of a side population of astrocytoma cells in response to temozolomide: laboratory investigation</article-title><source><italic>Journal of Neurosurgery</italic></source><year>2008</year><volume>109</volume><issue>5</issue><fpage>856</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.3171/jns/2008/109/11/0856</pub-id><pub-id pub-id-type="other">2-s2.0-58149166478</pub-id><pub-id pub-id-type="pmid">18976075</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Cheng</surname><given-names>L.</given-names></name><name><surname>Guryanova</surname><given-names>O. A.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Bao</surname><given-names>S.</given-names></name></person-group><article-title>Cancer stem cells in glioblastoma&#x02014;molecular signaling and therapeutic targeting</article-title><source><italic>Protein and Cell</italic></source><year>2010</year><volume>1</volume><issue>7</issue><fpage>638</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1007/s13238-010-0078-y</pub-id><pub-id pub-id-type="other">2-s2.0-79953189403</pub-id><pub-id pub-id-type="pmid">21203936</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciafr&#x000e8;</surname><given-names>S. A.</given-names></name><name><surname>Galardi</surname><given-names>S.</given-names></name><name><surname>Mangiola</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Extensive modulation of a set of microRNAs in primary glioblastoma</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>2005</year><volume>334</volume><issue>4</issue><fpage>1351</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2005.07.030</pub-id><pub-id pub-id-type="other">2-s2.0-23044464236</pub-id><pub-id pub-id-type="pmid">16039986</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J. A.</given-names></name><name><surname>Krichevsky</surname><given-names>A. M.</given-names></name><name><surname>Kosik</surname><given-names>K. S.</given-names></name></person-group><article-title>MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells</article-title><source><italic>Cancer Research</italic></source><year>2005</year><volume>65</volume><issue>14</issue><fpage>6029</fpage><lpage>6033</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.can-05-0137</pub-id><pub-id pub-id-type="other">2-s2.0-22244467087</pub-id><pub-id pub-id-type="pmid">16024602</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Pan</surname><given-names>T.</given-names></name><etal/></person-group><article-title>MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation</article-title><source><italic>Brain Research</italic></source><year>2010</year><volume>1312</volume><fpage>120</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2009.11.056</pub-id><pub-id pub-id-type="other">2-s2.0-73649147994</pub-id><pub-id pub-id-type="pmid">19948152</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B.</given-names></name><name><surname>Bian</surname><given-names>E.-B.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>New advances of microRNAs in glioma stem cells, with special emphasis on aberrant methylation of microRNAs</article-title><source><italic>Journal of Cellular Physiology</italic></source><year>2014</year><volume>229</volume><issue>9</issue><fpage>1141</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1002/jcp.24540</pub-id><pub-id pub-id-type="other">2-s2.0-84901218437</pub-id><pub-id pub-id-type="pmid">24374932</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>N.</given-names></name><name><surname>Xiao</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><etal/></person-group><article-title>miR-125b regulates the proliferation of glioblastoma stem cells by targeting E2F2</article-title><source><italic>FEBS Letters</italic></source><year>2012</year><volume>586</volume><issue>21</issue><fpage>3831</fpage><lpage>3839</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2012.08.023</pub-id><pub-id pub-id-type="other">2-s2.0-84868159450</pub-id><pub-id pub-id-type="pmid">22999819</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godlewski</surname><given-names>J.</given-names></name><name><surname>Nowicki</surname><given-names>M. O.</given-names></name><name><surname>Bronisz</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Targeting of the Bmi-1 oncogene/stem cell renewal factor by MicroRNA-128 inhibits glioma proliferation and self-renewal</article-title><source><italic>Cancer Research</italic></source><year>2008</year><volume>68</volume><issue>22</issue><fpage>9125</fpage><lpage>9130</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.can-08-2629</pub-id><pub-id pub-id-type="other">2-s2.0-56449126945</pub-id><pub-id pub-id-type="pmid">19010882</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papagiannakopoulos</surname><given-names>T.</given-names></name><name><surname>Friedmann-Morvinski</surname><given-names>D.</given-names></name><name><surname>Neveu</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases</article-title><source><italic>Oncogene</italic></source><year>2012</year><volume>31</volume><issue>15</issue><fpage>1884</fpage><lpage>1895</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.380</pub-id><pub-id pub-id-type="other">2-s2.0-84859757525</pub-id><pub-id pub-id-type="pmid">21874051</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Z.-M.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Yan</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1</article-title><source><italic>PLoS ONE</italic></source><year>2012</year><volume>7</volume><issue>3</issue><pub-id pub-id-type="publisher-id">e32709</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0032709</pub-id><pub-id pub-id-type="other">2-s2.0-84863361375</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Chao</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><etal/></person-group><article-title>MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a</article-title><source><italic>Journal of Molecular Medicine</italic></source><year>2009</year><volume>87</volume><issue>1</issue><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1007/s00109-008-0403-6</pub-id><pub-id pub-id-type="other">2-s2.0-57849155254</pub-id><pub-id pub-id-type="pmid">18810376</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>MiR-143 inhibits glycolysis and depletes stemness of glioblastoma stem-like cells</article-title><source><italic>Cancer Letters</italic></source><year>2013</year><volume>333</volume><issue>2</issue><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2013.01.039</pub-id><pub-id pub-id-type="other">2-s2.0-84876737635</pub-id><pub-id pub-id-type="pmid">23376635</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>MicroRNA-153 is tumor suppressive in glioblastoma stem cells</article-title><source><italic>Molecular Biology Reports</italic></source><year>2013</year><volume>40</volume><issue>4</issue><fpage>2789</fpage><lpage>2798</lpage><pub-id pub-id-type="doi">10.1007/s11033-012-2278-4</pub-id><pub-id pub-id-type="other">2-s2.0-84878421257</pub-id><pub-id pub-id-type="pmid">23397238</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kefas</surname><given-names>B.</given-names></name><name><surname>Godlewski</surname><given-names>J.</given-names></name><name><surname>Comeau</surname><given-names>L.</given-names></name><etal/></person-group><article-title>microRNA-7 inhibits the epidermal growth factor receptor and the akt pathway and is down-regulated in glioblastoma</article-title><source><italic>Cancer Research</italic></source><year>2008</year><volume>68</volume><issue>10</issue><fpage>3566</fpage><lpage>3572</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-6639</pub-id><pub-id pub-id-type="other">2-s2.0-45549089973</pub-id><pub-id pub-id-type="pmid">18483236</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Sun</surname><given-names>G.</given-names></name><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Fu</surname><given-names>X.</given-names></name></person-group><article-title>MiR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2</article-title><source><italic>NeuroMolecular Medicine</italic></source><year>2014</year><volume>16</volume><issue>2</issue><fpage>517</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1007/s12017-014-8305-y</pub-id><pub-id pub-id-type="other">2-s2.0-84901283474</pub-id><pub-id pub-id-type="pmid">24777293</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Guessous</surname><given-names>F.</given-names></name><name><surname>Ying</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes</article-title><source><italic>Cancer Research</italic></source><year>2009</year><volume>69</volume><issue>19</issue><fpage>7569</fpage><lpage>7576</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.can-09-0529</pub-id><pub-id pub-id-type="other">2-s2.0-70350221952</pub-id><pub-id pub-id-type="pmid">19773441</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guessous</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Kofman</surname><given-names>A.</given-names></name><etal/></person-group><article-title>microRNA-34a is tumor suppressive in brain tumors and glioma stem cells</article-title><source><italic>Cell Cycle</italic></source><year>2010</year><volume>9</volume><issue>6</issue><fpage>1031</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.4161/cc.9.6.10987</pub-id><pub-id pub-id-type="other">2-s2.0-77953498262</pub-id><pub-id pub-id-type="pmid">20190569</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathod</surname><given-names>S. S.</given-names></name><name><surname>Rani</surname><given-names>S. B.</given-names></name><name><surname>Khan</surname><given-names>M.</given-names></name><name><surname>Muzumdar</surname><given-names>D.</given-names></name><name><surname>Shiras</surname><given-names>A.</given-names></name></person-group><article-title>Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways</article-title><source><italic>FEBS Open Bio</italic></source><year>2014</year><volume>4</volume><fpage>485</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1016/j.fob.2014.05.002</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Tian</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Differential effects of miR-34c-3p and miR-34c-5p on the proliferation, apoptosis and invasion of glioma cells</article-title><source><italic>Oncology Letters</italic></source><year>2013</year><volume>6</volume><issue>5</issue><fpage>1447</fpage><lpage>1452</lpage><pub-id pub-id-type="doi">10.3892/ol.2013.1579</pub-id><pub-id pub-id-type="other">2-s2.0-84884489631</pub-id><pub-id pub-id-type="pmid">24179539</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>J.</given-names></name><name><surname>Bachoo</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>C.-L.</given-names></name></person-group><article-title>MicroRNA-146a inhibits glioma development by targeting Notch1</article-title><source><italic>Molecular and Cellular Biology</italic></source><year>2011</year><volume>31</volume><issue>17</issue><fpage>3584</fpage><lpage>3592</lpage><pub-id pub-id-type="doi">10.1128/mcb.05821-11</pub-id><pub-id pub-id-type="other">2-s2.0-80052319304</pub-id><pub-id pub-id-type="pmid">21730286</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>X.-R.</given-names></name><name><surname>Chen</surname><given-names>F.-F.</given-names></name><etal/></person-group><article-title>MicroRNA-107 inhibits U87 glioma stem cells growth and invasion</article-title><source><italic>Cellular and Molecular Neurobiology</italic></source><year>2013</year><volume>33</volume><issue>5</issue><fpage>651</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1007/s10571-013-9927-6</pub-id><pub-id pub-id-type="other">2-s2.0-84878704825</pub-id><pub-id pub-id-type="pmid">23572380</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kefas</surname><given-names>B.</given-names></name><name><surname>Comeau</surname><given-names>L.</given-names></name><name><surname>Floyd</surname><given-names>D. H.</given-names></name><etal/></person-group><article-title>The neuronal microRNA miR-326 acts in a feedback loop with Notch and has therapeutic potential against brain tumors</article-title><source><italic>Journal of Neuroscience</italic></source><year>2009</year><volume>29</volume><issue>48</issue><fpage>15161</fpage><lpage>15168</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4966-09.2009</pub-id><pub-id pub-id-type="other">2-s2.0-72849108572</pub-id><pub-id pub-id-type="pmid">19955368</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Luo</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>miR-622 suppresses proliferation, invasion and migration by directly targeting activating transcription factor 2 in glioma cells</article-title><source><italic>Journal of Neuro-Oncology</italic></source><year>2015</year><volume>121</volume><issue>1</issue><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/s11060-014-1607-y</pub-id><pub-id pub-id-type="pmid">25258251</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><etal/></person-group><article-title>MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Kruppel-like factor 4</article-title><source><italic>Cancer Letters</italic></source><year>2014</year><volume>355</volume><issue>1</issue><fpage>85</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">25218589</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><etal/></person-group><article-title>MicroRNA-218 inhibits glioma invasion, migration, proliferation, and Cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1</article-title><source><italic>Cancer Research</italic></source><year>2013</year><volume>73</volume><issue>19</issue><fpage>6046</fpage><lpage>6055</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-0358</pub-id><pub-id pub-id-type="other">2-s2.0-84885083594</pub-id><pub-id pub-id-type="pmid">23950210</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silber</surname><given-names>J.</given-names></name><name><surname>Lim</surname><given-names>D. A.</given-names></name><name><surname>Petritsch</surname><given-names>C.</given-names></name><etal/></person-group><article-title>miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells</article-title><source><italic>BMC Medicine</italic></source><year>2008</year><volume>6, article 14</volume><pub-id pub-id-type="doi">10.1186/1741-7015-6-14</pub-id><pub-id pub-id-type="other">2-s2.0-48949116262</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>H.</given-names></name><name><surname>Cheung</surname><given-names>W. K. C.</given-names></name><name><surname>Ng</surname><given-names>S. S.</given-names></name><etal/></person-group><article-title>Loss of brain-enriched miR-124 microRNA enhances stem-like traits and invasiveness of glioma cells</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2012</year><volume>287</volume><issue>13</issue><fpage>9962</fpage><lpage>9971</lpage><pub-id pub-id-type="doi">10.1074/jbc.m111.332627</pub-id><pub-id pub-id-type="other">2-s2.0-84858992906</pub-id><pub-id pub-id-type="pmid">22253443</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bier</surname><given-names>A.</given-names></name><name><surname>Giladi</surname><given-names>N.</given-names></name><name><surname>Kronfeld</surname><given-names>N.</given-names></name><etal/></person-group><article-title>MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1</article-title><source><italic>Oncotarget</italic></source><year>2013</year><volume>4</volume><issue>5</issue><fpage>665</fpage><lpage>676</lpage><pub-id pub-id-type="other">2-s2.0-84880298578</pub-id><pub-id pub-id-type="pmid">23714687</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamim</surname><given-names>S.</given-names></name><name><surname>Vo</surname><given-names>D. T.</given-names></name><name><surname>Uren</surname><given-names>P. J.</given-names></name><etal/></person-group><article-title>Genomic analyses reveal broad impact of miR-137 on genes associated with malignant transformation and neuronal differentiation in glioblastoma cells</article-title><source><italic>PLoS ONE</italic></source><year>2014</year><volume>9</volume><issue>1</issue><pub-id pub-id-type="publisher-id">e85591</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0085591</pub-id><pub-id pub-id-type="other">2-s2.0-84899835835</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>Y.</given-names></name><name><surname>Nan</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>L.</given-names></name><etal/></person-group><article-title>MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human glioma</article-title><source><italic>International Journal of Oncology</italic></source><year>2012</year><volume>40</volume><issue>4</issue><fpage>1105</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.3892/ijo.2011.1306</pub-id><pub-id pub-id-type="other">2-s2.0-84863392564</pub-id><pub-id pub-id-type="pmid">22179124</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gal</surname><given-names>H.</given-names></name><name><surname>Pandi</surname><given-names>G.</given-names></name><name><surname>Kanner</surname><given-names>A. A.</given-names></name><etal/></person-group><article-title>MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>2008</year><volume>376</volume><issue>1</issue><fpage>86</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.08.107</pub-id><pub-id pub-id-type="other">2-s2.0-52049096593</pub-id><pub-id pub-id-type="pmid">18765229</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Jun</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>MicroRNA-200b targets CREB1 and suppresses cell growth in human malignant glioma</article-title><source><italic>Molecular and Cellular Biochemistry</italic></source><year>2013</year><volume>379</volume><issue>1-2</issue><fpage>51</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1007/s11010-013-1626-6</pub-id><pub-id pub-id-type="other">2-s2.0-84878428412</pub-id><pub-id pub-id-type="pmid">23543137</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Men</surname><given-names>D.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Decreased expression of microRNA-200b is an independent unfavorable prognostic factor for glioma patients</article-title><source><italic>Cancer Epidemiology</italic></source><year>2014</year><volume>38</volume><issue>2</issue><fpage>152</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.canep.2014.01.003</pub-id><pub-id pub-id-type="other">2-s2.0-84898021452</pub-id><pub-id pub-id-type="pmid">24559637</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Tang</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>MiR-200b as a prognostic factor targets multiple members of RAB family in glioma</article-title><source><italic>Medical Oncology</italic></source><year>2014</year><volume>31</volume><issue>3, article 859</issue><pub-id pub-id-type="doi">10.1007/s12032-014-0859-x</pub-id><pub-id pub-id-type="other">2-s2.0-84892936699</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Deng</surname><given-names>L.</given-names></name><etal/></person-group><article-title>MiR-200a impairs glioma cell growth, migration, and invasion by targeting SIM2-s</article-title><source><italic>NeuroReport</italic></source><year>2014</year><volume>25</volume><issue>1</issue><fpage>12</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1097/wnr.0000000000000032</pub-id><pub-id pub-id-type="other">2-s2.0-84889879789</pub-id><pub-id pub-id-type="pmid">24162743</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>M.-F.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells</article-title><source><italic>PLoS ONE</italic></source><year>2012</year><volume>7</volume><issue>4</issue><pub-id pub-id-type="publisher-id">e36248</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0036248</pub-id><pub-id pub-id-type="other">2-s2.0-84860448293</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guessous</surname><given-names>F.</given-names></name><name><surname>Alvarado-Velez</surname><given-names>M.</given-names></name><name><surname>Marcinkiewicz</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Oncogenic effects of miR-10b in glioblastoma stem cells</article-title><source><italic>Journal of Neuro-Oncology</italic></source><year>2013</year><volume>112</volume><issue>2</issue><fpage>153</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1007/s11060-013-1047-0</pub-id><pub-id pub-id-type="other">2-s2.0-84879631306</pub-id><pub-id pub-id-type="pmid">23307328</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Thomson</surname><given-names>J. M.</given-names></name><name><surname>Hemann</surname><given-names>M. T.</given-names></name><etal/></person-group><article-title>A microRNA polycistron as a potential human oncogene</article-title><source><italic>Nature</italic></source><year>2005</year><volume>435</volume><issue>7043</issue><fpage>828</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1038/nature03552</pub-id><pub-id pub-id-type="other">2-s2.0-20444467290</pub-id><pub-id pub-id-type="pmid">15944707</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schraivogel</surname><given-names>D.</given-names></name><name><surname>Weinmann</surname><given-names>L.</given-names></name><name><surname>Beier</surname><given-names>D.</given-names></name><etal/></person-group><article-title>CAMTA1 is a novel tumour suppressor regulated by miR-9/9<sup>&#x02217;</sup> in glioblastoma stem cells</article-title><source><italic>The EMBO Journal</italic></source><year>2011</year><volume>30</volume><issue>20</issue><fpage>4309</fpage><lpage>4322</lpage><pub-id pub-id-type="doi">10.1038/emboj.2011.301</pub-id><pub-id pub-id-type="other">2-s2.0-80054937128</pub-id><pub-id pub-id-type="pmid">21857646</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>A.</given-names></name><name><surname>Campos</surname><given-names>B.</given-names></name><name><surname>Meier</surname><given-names>J.</given-names></name><etal/></person-group><article-title>De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures</article-title><source><italic>Oncogene</italic></source><year>2010</year><volume>29</volume><issue>23</issue><fpage>3411</fpage><lpage>3422</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.83</pub-id><pub-id pub-id-type="other">2-s2.0-77953478056</pub-id><pub-id pub-id-type="pmid">20305691</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miele</surname><given-names>E.</given-names></name><name><surname>Buttarelli</surname><given-names>F. R.</given-names></name><name><surname>Arcella</surname><given-names>A.</given-names></name><etal/></person-group><article-title>High-throughput microRNA profiling of pediatric high-grade gliomas</article-title><source><italic>Neuro-Oncology</italic></source><year>2014</year><volume>16</volume><issue>2</issue><fpage>228</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1093/neuonc/not215</pub-id><pub-id pub-id-type="other">2-s2.0-84893122766</pub-id><pub-id pub-id-type="pmid">24305714</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>X. H. D.</given-names></name><name><surname>Nama</surname><given-names>S.</given-names></name><name><surname>Gopal</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Targeting glioma stem cells by functional inhibition of a prosurvival oncomiR-138 in malignant gliomas</article-title><source><italic>Cell Reports</italic></source><year>2012</year><volume>2</volume><issue>3</issue><fpage>591</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2012.07.012</pub-id><pub-id pub-id-type="other">2-s2.0-84866905323</pub-id><pub-id pub-id-type="pmid">22921398</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Floyd</surname><given-names>D. H.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Dey</surname><given-names>B. K.</given-names></name><etal/></person-group><article-title>Novel anti-apoptotic microRNAs 582-5p and 363 promote human glioblastoma stem cell survival via direct inhibition of caspase 3, caspase 9, and Bim</article-title><source><italic>PLoS ONE</italic></source><year>2014</year><volume>9</volume><issue>5</issue><pub-id pub-id-type="publisher-id">e96239</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0096239</pub-id><pub-id pub-id-type="other">2-s2.0-84900522706</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Xue</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><etal/></person-group><article-title>MiR-330-mediated regulation of SH3GL2 expression enhances malignant behaviors of glioblastoma stem cells by activating ERK and PI3K/AKT signaling pathways</article-title><source><italic>PLoS ONE</italic></source><year>2014</year><volume>9</volume><issue>4</issue><pub-id pub-id-type="publisher-id">e95060</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0095060.g001</pub-id><pub-id pub-id-type="other">2-s2.0-84899674559</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsushima</surname><given-names>K.</given-names></name><name><surname>Shinjo</surname><given-names>K.</given-names></name><name><surname>Natsume</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Contribution of microRNA-1275 to Claudin11 protein suppression via a polycomb-mediated silencing mechanism in human glioma stem-like cells</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2012</year><volume>287</volume><issue>33</issue><fpage>27396</fpage><lpage>27406</lpage><pub-id pub-id-type="doi">10.1074/jbc.m112.359109</pub-id><pub-id pub-id-type="other">2-s2.0-84864992390</pub-id><pub-id pub-id-type="pmid">22736761</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>D. N.</given-names></name><name><surname>Ohgaki</surname><given-names>H.</given-names></name><name><surname>Wiestler</surname><given-names>O. D.</given-names></name><etal/></person-group><article-title>The 2007 WHO classification of tumours of the central nervous system</article-title><source><italic>Acta Neuropathologica</italic></source><year>2007</year><volume>114</volume><issue>2</issue><fpage>97</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">17618441</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paugh</surname><given-names>B. S.</given-names></name><name><surname>Qu</surname><given-names>C.</given-names></name><name><surname>Jones</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2010</year><volume>28</volume><issue>18</issue><fpage>3061</fpage><lpage>3068</lpage><pub-id pub-id-type="doi">10.1200/jco.2009.26.7252</pub-id><pub-id pub-id-type="other">2-s2.0-77954596239</pub-id><pub-id pub-id-type="pmid">20479398</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birks</surname><given-names>D. K.</given-names></name><name><surname>Barton</surname><given-names>V. N.</given-names></name><name><surname>Donson</surname><given-names>A. M.</given-names></name><name><surname>Handler</surname><given-names>M. H.</given-names></name><name><surname>Vibhakar</surname><given-names>R.</given-names></name><name><surname>Foreman</surname><given-names>N. K.</given-names></name></person-group><article-title>Survey of MicroRNA expression in pediatric brain tumors</article-title><source><italic>Pediatric Blood and Cancer</italic></source><year>2011</year><volume>56</volume><issue>2</issue><fpage>211</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1002/pbc.22723</pub-id><pub-id pub-id-type="other">2-s2.0-78650139005</pub-id><pub-id pub-id-type="pmid">21157891</pub-id></element-citation></ref><ref id="B109"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatta</surname><given-names>G.</given-names></name><name><surname>Zigon</surname><given-names>G.</given-names></name><name><surname>Capocaccia</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Survival of European children and young adults with cancer diagnosed 1995&#x02013;2002</article-title><source><italic>European Journal of Cancer</italic></source><year>2009</year><volume>45</volume><issue>6</issue><fpage>992</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2008.11.042</pub-id><pub-id pub-id-type="other">2-s2.0-62549126896</pub-id><pub-id pub-id-type="pmid">19231160</pub-id></element-citation></ref><ref id="B110"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>D. W.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>The genetic landscape of the childhood cancer medulloblastoma</article-title><source><italic>Science</italic></source><year>2011</year><volume>331</volume><issue>6016</issue><fpage>435</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1126/science.1198056</pub-id><pub-id pub-id-type="pmid">21163964</pub-id></element-citation></ref><ref id="B111"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>Y.-J.</given-names></name><name><surname>Tsherniak</surname><given-names>A.</given-names></name><name><surname>Tamayo</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2011</year><volume>29</volume><issue>11</issue><fpage>1424</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.28.5148</pub-id><pub-id pub-id-type="other">2-s2.0-79954991010</pub-id><pub-id pub-id-type="pmid">21098324</pub-id></element-citation></ref><ref id="B112"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellison</surname><given-names>D. W.</given-names></name><name><surname>Dalton</surname><given-names>J.</given-names></name><name><surname>Kocak</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups</article-title><source><italic>Acta Neuropathologica</italic></source><year>2011</year><volume>121</volume><issue>3</issue><fpage>381</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1007/s00401-011-0800-8</pub-id><pub-id pub-id-type="other">2-s2.0-79954444747</pub-id><pub-id pub-id-type="pmid">21267586</pub-id></element-citation></ref><ref id="B113"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Northcott</surname><given-names>P. A.</given-names></name><name><surname>Shih</surname><given-names>D. J. H.</given-names></name><name><surname>Remke</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples</article-title><source><italic>Acta Neuropathologica</italic></source><year>2012</year><volume>123</volume><issue>4</issue><fpage>615</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1007/s00401-011-0899-7</pub-id><pub-id pub-id-type="other">2-s2.0-84862680481</pub-id><pub-id pub-id-type="pmid">22057785</pub-id></element-citation></ref><ref id="B114"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>S. L.</given-names></name><name><surname>Reddick</surname><given-names>W. E.</given-names></name><name><surname>Gajjar</surname><given-names>A.</given-names></name></person-group><article-title>Understanding the cognitive impact on children who are treated for medulloblastoma</article-title><source><italic>Journal of Pediatric Psychology</italic></source><year>2007</year><volume>32</volume><issue>9</issue><fpage>1040</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1093/jpepsy/jsl056</pub-id><pub-id pub-id-type="other">2-s2.0-35448958465</pub-id><pub-id pub-id-type="pmid">17329318</pub-id></element-citation></ref><ref id="B115"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaswamy</surname><given-names>V.</given-names></name><name><surname>Remke</surname><given-names>M.</given-names></name><name><surname>Bouffet</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis</article-title><source><italic>The Lancet Oncology</italic></source><year>2013</year><volume>14</volume><issue>12</issue><fpage>1200</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70449-2</pub-id><pub-id pub-id-type="pmid">24140199</pub-id></element-citation></ref><ref id="B116"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidal</surname><given-names>D. O.</given-names></name><name><surname>Marques</surname><given-names>M. M. C.</given-names></name><name><surname>Lopes</surname><given-names>L. F.</given-names></name><name><surname>Reis</surname><given-names>R. M.</given-names></name></person-group><article-title>The role of microRNAs in medulloblastoma</article-title><source><italic>Pediatric Hematology and Oncology</italic></source><year>2013</year><volume>30</volume><issue>5</issue><fpage>367</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.3109/08880018.2013.783890</pub-id><pub-id pub-id-type="other">2-s2.0-84880359331</pub-id><pub-id pub-id-type="pmid">23528184</pub-id></element-citation></ref><ref id="B117"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferretti</surname><given-names>E.</given-names></name><name><surname>De Smaele</surname><given-names>E.</given-names></name><name><surname>Miele</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells</article-title><source><italic>The EMBO Journal</italic></source><year>2008</year><volume>27</volume><issue>19</issue><fpage>2616</fpage><lpage>2627</lpage><pub-id pub-id-type="doi">10.1038/emboj.2008.172</pub-id><pub-id pub-id-type="other">2-s2.0-53549129980</pub-id><pub-id pub-id-type="pmid">18756266</pub-id></element-citation></ref><ref id="B118"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferretti</surname><given-names>E.</given-names></name><name><surname>de Smaele</surname><given-names>E.</given-names></name><name><surname>Po</surname><given-names>A.</given-names></name><etal/></person-group><article-title>MicroRNA profiling in human medulloblastoma</article-title><source><italic>International Journal of Cancer</italic></source><year>2009</year><volume>124</volume><issue>3</issue><fpage>568</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1002/ijc.23948</pub-id><pub-id pub-id-type="other">2-s2.0-58149279841</pub-id></element-citation></ref><ref id="B119"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierson</surname><given-names>J.</given-names></name><name><surname>Hostager</surname><given-names>B.</given-names></name><name><surname>Fan</surname><given-names>R.</given-names></name><name><surname>Vibhakar</surname><given-names>R.</given-names></name></person-group><article-title>Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma</article-title><source><italic>Journal of Neuro-Oncology</italic></source><year>2008</year><volume>90</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s11060-008-9624-3</pub-id><pub-id pub-id-type="other">2-s2.0-46349109152</pub-id><pub-id pub-id-type="pmid">18607543</pub-id></element-citation></ref><ref id="B120"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>K. K. W.</given-names></name><name><surname>Pang</surname><given-names>J. C. S.</given-names></name><name><surname>Ching</surname><given-names>A. K. K.</given-names></name><etal/></person-group><article-title>miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1</article-title><source><italic>Human Pathology</italic></source><year>2009</year><volume>40</volume><issue>9</issue><fpage>1234</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2009.02.003</pub-id><pub-id pub-id-type="other">2-s2.0-67349155172</pub-id><pub-id pub-id-type="pmid">19427019</pub-id></element-citation></ref><ref id="B123"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkataraman</surname><given-names>S.</given-names></name><name><surname>Birks</surname><given-names>D. K.</given-names></name><name><surname>Balakrishnan</surname><given-names>I.</given-names></name><etal/></person-group><article-title>MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma</article-title><source><italic>Journal of Biological Chemistry</italic></source><year>2013</year><volume>288</volume><issue>3</issue><fpage>1918</fpage><lpage>1928</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.396762</pub-id><pub-id pub-id-type="other">2-s2.0-84872726735</pub-id><pub-id pub-id-type="pmid">23212916</pub-id></element-citation></ref><ref id="B124"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garzia</surname><given-names>L.</given-names></name><name><surname>Andolfo</surname><given-names>I.</given-names></name><name><surname>Cusanelli</surname><given-names>E.</given-names></name><etal/></person-group><article-title>MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma</article-title><source><italic>PLoS ONE</italic></source><year>2009</year><volume>4</volume><issue>3</issue><pub-id pub-id-type="publisher-id">e4998</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0004998</pub-id><pub-id pub-id-type="other">2-s2.0-63449135077</pub-id></element-citation></ref><ref id="B125"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andolfo</surname><given-names>I.</given-names></name><name><surname>Liguori</surname><given-names>L.</given-names></name><name><surname>De Antonellis</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma</article-title><source><italic>Neuro-Oncology</italic></source><year>2012</year><volume>14</volume><issue>5</issue><fpage>596</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nos002</pub-id><pub-id pub-id-type="other">2-s2.0-84860378895</pub-id><pub-id pub-id-type="pmid">22411914</pub-id></element-citation></ref><ref id="B126"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Antonellis</surname><given-names>P.</given-names></name><name><surname>Medaglia</surname><given-names>C.</given-names></name><name><surname>Cusanelli</surname><given-names>E.</given-names></name><etal/></person-group><article-title>MiR-34a targeting of Notch ligand delta-like 1 impairs CD15<sup>+</sup>/CD133<sup>+</sup> tumor-propagating cells and supports neural differentiation in medulloblastoma</article-title><source><italic>PLoS ONE</italic></source><year>2011</year><volume>6</volume><issue>9</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0024584</pub-id></element-citation></ref><ref id="B127"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weeraratne</surname><given-names>S. D.</given-names></name><name><surname>Amani</surname><given-names>V.</given-names></name><name><surname>Neiss</surname><given-names>A.</given-names></name><etal/></person-group><article-title>miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma</article-title><source><italic>Neuro-Oncology</italic></source><year>2011</year><volume>13</volume><issue>2</issue><fpage>165</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1093/neuonc/noq179</pub-id><pub-id pub-id-type="other">2-s2.0-79951838573</pub-id><pub-id pub-id-type="pmid">21177782</pub-id></element-citation></ref><ref id="B128"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thor</surname><given-names>T.</given-names></name><name><surname>K&#x000fc;nkele</surname><given-names>A.</given-names></name><name><surname>Pajtler</surname><given-names>K. W.</given-names></name><etal/></person-group><article-title>MiR-34a deficiency accelerates medulloblastoma formation <italic>in vivo</italic></article-title><source><italic>International Journal of Cancer</italic></source><year>2015</year><volume>136</volume><issue>10</issue><fpage>2293</fpage><lpage>2303</lpage><pub-id pub-id-type="doi">10.1002/ijc.29294</pub-id></element-citation></ref><ref id="B133"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gokhale</surname><given-names>A.</given-names></name><name><surname>Kunder</surname><given-names>R.</given-names></name><name><surname>Goel</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway</article-title><source><italic>Journal of Cancer Research and Therapeutics</italic></source><year>2010</year><volume>6</volume><issue>4</issue><fpage>521</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.4103/0973-1482.77072</pub-id><pub-id pub-id-type="other">2-s2.0-79952430095</pub-id><pub-id pub-id-type="pmid">21358093</pub-id></element-citation></ref><ref id="B134"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S. K.</given-names></name><name><surname>Clarke</surname><given-names>I. D.</given-names></name><name><surname>Terasaki</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Identification of a cancer stem cell in human brain tumors</article-title><source><italic>Cancer Research</italic></source><year>2003</year><volume>63</volume><issue>18</issue><fpage>5821</fpage><lpage>5828</lpage><pub-id pub-id-type="other">2-s2.0-0141842674</pub-id><pub-id pub-id-type="pmid">14522905</pub-id></element-citation></ref><ref id="B135"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Remke</surname><given-names>M.</given-names></name><name><surname>Bhat</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma</article-title><source><italic>Oncotarget</italic></source><year>2015</year><volume>6</volume><issue>5</issue><fpage>2709</fpage><lpage>2724</lpage><pub-id pub-id-type="pmid">25576913</pub-id></element-citation></ref><ref id="B136"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemmesi</surname><given-names>K.</given-names></name><name><surname>Squadrito</surname><given-names>M. L.</given-names></name><name><surname>Mestdagh</surname><given-names>P.</given-names></name><etal/></person-group><article-title>miR-135a inhibits cancer stem cell-driven medulloblastoma development by directly repressing Arhgef6 expression</article-title><source><italic>Stem Cells</italic></source><year>2015</year><volume>33</volume><issue>5</issue><fpage>1377</fpage><lpage>1389</lpage><pub-id pub-id-type="doi">10.1002/stem.1958</pub-id><pub-id pub-id-type="pmid">25639612</pub-id></element-citation></ref><ref id="B121"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uziel</surname><given-names>T.</given-names></name><name><surname>Karginov</surname><given-names>F. V.</given-names></name><name><surname>Xie</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2009</year><volume>106</volume><issue>8</issue><fpage>2812</fpage><lpage>2817</lpage><pub-id pub-id-type="doi">10.1073/pnas.0809579106</pub-id><pub-id pub-id-type="other">2-s2.0-62449294691</pub-id><pub-id pub-id-type="pmid">19196975</pub-id></element-citation></ref><ref id="B122"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Northcott</surname><given-names>P. A.</given-names></name><name><surname>Fernandez-L</surname><given-names>A.</given-names></name><name><surname>Hagan</surname><given-names>J. P.</given-names></name><etal/></person-group><article-title>The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors</article-title><source><italic>Cancer Research</italic></source><year>2009</year><volume>69</volume><issue>8</issue><fpage>3249</fpage><lpage>3255</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-4710</pub-id><pub-id pub-id-type="other">2-s2.0-65249186793</pub-id><pub-id pub-id-type="pmid">19351822</pub-id></element-citation></ref><ref id="B129"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>A. H. C.</given-names></name><name><surname>Milde</surname><given-names>T.</given-names></name><name><surname>Remke</surname><given-names>M.</given-names></name><etal/></person-group><article-title>MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma</article-title><source><italic>Acta Neuropathologica</italic></source><year>2012</year><volume>123</volume><issue>4</issue><fpage>529</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1007/s00401-011-0924-x</pub-id><pub-id pub-id-type="other">2-s2.0-84862650336</pub-id><pub-id pub-id-type="pmid">22134538</pub-id></element-citation></ref><ref id="B130"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.-Y.</given-names></name><name><surname>Yang</surname><given-names>Y.-P.</given-names></name><name><surname>Huang</surname><given-names>M.-C.</given-names></name><etal/></person-group><article-title>MicroRNA142-3p promotes tumor-initiating and radioresistant properties in malignant pediatric brain tumors</article-title><source><italic>Cell Transplantation</italic></source><year>2014</year><volume>23</volume><issue>4-5</issue><fpage>669</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.3727/096368914X678364</pub-id><pub-id pub-id-type="other">2-s2.0-84900453296</pub-id><pub-id pub-id-type="pmid">24816458</pub-id></element-citation></ref><ref id="B131"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Cheng</surname><given-names>S. Y.</given-names></name></person-group><article-title>The miR-183 approximately 96 approximately 182 cluster promotes tumorigenesis in a mouse model of medulloblastoma</article-title><source><italic>Journal of Biomedical Research</italic></source><year>2013</year><volume>27</volume><issue>6</issue><fpage>486</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.7555/jbr.27.20130010</pub-id><pub-id pub-id-type="pmid">24285947</pub-id></element-citation></ref><ref id="B132"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunder</surname><given-names>E.</given-names></name><name><surname>D'Ambrosio</surname><given-names>R.</given-names></name><name><surname>Fiaschetti</surname><given-names>G.</given-names></name><etal/></person-group><article-title>microRNA-21 suppression impedes medulloblastoma cell migration</article-title><source><italic>European Journal of Cancer</italic></source><year>2011</year><volume>47</volume><issue>16</issue><fpage>2479</fpage><lpage>2490</lpage><pub-id pub-id-type="other">2-s2.0-80054892774</pub-id><pub-id pub-id-type="pmid">21775132</pub-id></element-citation></ref><ref id="B137"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Ryan</surname><given-names>S. L.</given-names></name><name><surname>Elliott</surname><given-names>D. J.</given-names></name><etal/></person-group><article-title>Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma</article-title><source><italic>PLoS ONE</italic></source><year>2009</year><volume>4</volume><issue>7</issue><pub-id pub-id-type="publisher-id">e6159</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0006159</pub-id><pub-id pub-id-type="other">2-s2.0-67650243241</pub-id></element-citation></ref><ref id="B138"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karavitaki</surname><given-names>N.</given-names></name><name><surname>Cudlip</surname><given-names>S.</given-names></name><name><surname>Adams</surname><given-names>C. B. T.</given-names></name><name><surname>Wass</surname><given-names>J. A. H.</given-names></name></person-group><article-title>Craniopharyngiomas</article-title><source><italic>Endocrine Reviews</italic></source><year>2006</year><volume>27</volume><issue>4</issue><fpage>371</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1210/er.2006-0002</pub-id><pub-id pub-id-type="other">2-s2.0-33744904755</pub-id><pub-id pub-id-type="pmid">16543382</pub-id></element-citation></ref><ref id="B139"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>E. H.</given-names></name><name><surname>Feldt-Rasmussen</surname><given-names>U.</given-names></name><name><surname>Poulsgaard</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Incidence of craniopharyngioma in Denmark (<italic>n</italic> = 189) and estimated world incidence of craniopharyngioma in children and adults</article-title><source><italic>Journal of Neuro-Oncology</italic></source><year>2011</year><volume>104</volume><issue>3</issue><fpage>755</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1007/s11060-011-0540-6</pub-id><pub-id pub-id-type="other">2-s2.0-80052611179</pub-id><pub-id pub-id-type="pmid">21336771</pub-id></element-citation></ref><ref id="B140"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunin</surname><given-names>G. R.</given-names></name><name><surname>Surawicz</surname><given-names>T. S.</given-names></name><name><surname>Witman</surname><given-names>P. A.</given-names></name><name><surname>Preston-Martin</surname><given-names>S.</given-names></name><name><surname>Davis</surname><given-names>F.</given-names></name><name><surname>Bruner</surname><given-names>J. M.</given-names></name></person-group><article-title>The descriptive epidemiology of craniopharyngioma</article-title><source><italic>Journal of Neurosurgery</italic></source><year>1998</year><volume>89</volume><issue>4</issue><fpage>547</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.3171/jns.1998.89.4.0547</pub-id><pub-id pub-id-type="other">2-s2.0-0031707099</pub-id><pub-id pub-id-type="pmid">9761047</pub-id></element-citation></ref><ref id="B141"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andoniadou</surname><given-names>C. L.</given-names></name><name><surname>Gaston-Massuet</surname><given-names>C.</given-names></name><name><surname>Reddy</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma</article-title><source><italic>Acta Neuropathologica</italic></source><year>2012</year><volume>124</volume><issue>2</issue><fpage>259</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1007/s00401-012-0957-9</pub-id><pub-id pub-id-type="other">2-s2.0-84865866414</pub-id><pub-id pub-id-type="pmid">22349813</pub-id></element-citation></ref><ref id="B142"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Gleiberman</surname><given-names>A. S.</given-names></name><name><surname>Rosenfeld</surname><given-names>M. G.</given-names></name></person-group><article-title>Molecular physiology of pituitary development: signaling and transcriptional networks</article-title><source><italic>Physiological Reviews</italic></source><year>2007</year><volume>87</volume><issue>3</issue><fpage>933</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1152/physrev.00006.2006</pub-id><pub-id pub-id-type="other">2-s2.0-34447518530</pub-id><pub-id pub-id-type="pmid">17615393</pub-id></element-citation></ref><ref id="B143"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campanini</surname><given-names>M. L.</given-names></name><name><surname>Colli</surname><given-names>L. M.</given-names></name><name><surname>Paixao</surname><given-names>B. M. C.</given-names></name><etal/></person-group><article-title>CTNNB1 gene mutations, pituitary transcription factors, and MicroRNA expression involvement in the pathogenesis of adamantinomatous craniopharyngiomas</article-title><source><italic>Hormones and Cancer</italic></source><year>2010</year><volume>1</volume><issue>4</issue><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1007/s12672-010-0041-7</pub-id><pub-id pub-id-type="other">2-s2.0-78650213872</pub-id><pub-id pub-id-type="pmid">21761366</pub-id></element-citation></ref><ref id="B144"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>Y.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Xiang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>miR-449b inhibits the proliferation of SW1116 colon cancer stem cells through downregulation of CCND1 and E2F3 expression</article-title><source><italic>Oncology Reports</italic></source><year>2013</year><volume>30</volume><issue>1</issue><fpage>399</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.3892/or.2013.2465</pub-id><pub-id pub-id-type="other">2-s2.0-84878179309</pub-id><pub-id pub-id-type="pmid">23674142</pub-id></element-citation></ref><ref id="B145"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>J.</given-names></name><name><surname>Luo</surname><given-names>H.</given-names></name><name><surname>Pu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Methylation mediated silencing of miR-23b expression and its role in glioma stem cells</article-title><source><italic>Neuroscience Letters</italic></source><year>2012</year><volume>528</volume><issue>2</issue><fpage>185</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2012.08.055</pub-id><pub-id pub-id-type="other">2-s2.0-84867695818</pub-id><pub-id pub-id-type="pmid">22982144</pub-id></element-citation></ref><ref id="B146"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finlay-Schultz</surname><given-names>J.</given-names></name><name><surname>Cittelly</surname><given-names>D. M.</given-names></name><name><surname>Hendricks</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a</article-title><source><italic>Oncogene</italic></source><year>2014</year><pub-id pub-id-type="doi">10.1038/onc.2014.298</pub-id></element-citation></ref><ref id="B147"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>T. S.</given-names></name><name><surname>Vera-Bolanos</surname><given-names>E.</given-names></name><name><surname>Gilbert</surname><given-names>M. R.</given-names></name></person-group><article-title>Clinical course of adult patients with ependymoma: results of the Adult Ependymoma Outcomes Project</article-title><source><italic>Cancer</italic></source><year>2011</year><volume>117</volume><issue>22</issue><fpage>5133</fpage><lpage>5141</lpage><pub-id pub-id-type="doi">10.1002/cncr.26181</pub-id><pub-id pub-id-type="other">2-s2.0-80555155584</pub-id><pub-id pub-id-type="pmid">21538344</pub-id></element-citation></ref><ref id="B148"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poppleton</surname><given-names>H.</given-names></name><name><surname>Gilbertson</surname><given-names>R. J.</given-names></name></person-group><article-title>Stem cells of ependymoma</article-title><source><italic>British Journal of Cancer</italic></source><year>2007</year><volume>96</volume><issue>1</issue><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6603519</pub-id><pub-id pub-id-type="other">2-s2.0-33846189405</pub-id><pub-id pub-id-type="pmid">17179988</pub-id></element-citation></ref><ref id="B149"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>M. D.</given-names></name><name><surname>Poppleton</surname><given-names>H.</given-names></name><name><surname>Fuller</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Radial glia cells are candidate stem cells of ependymoma</article-title><source><italic>Cancer Cell</italic></source><year>2005</year><volume>8</volume><issue>4</issue><fpage>323</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2005.09.001</pub-id><pub-id pub-id-type="other">2-s2.0-26644435531</pub-id><pub-id pub-id-type="pmid">16226707</pub-id></element-citation></ref><ref id="B150"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabori</surname><given-names>U.</given-names></name><name><surname>Wong</surname><given-names>V.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma</article-title><source><italic>British Journal of Cancer</italic></source><year>2008</year><volume>99</volume><issue>7</issue><fpage>1129</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604652</pub-id><pub-id pub-id-type="other">2-s2.0-53049110280</pub-id><pub-id pub-id-type="pmid">18797459</pub-id></element-citation></ref><ref id="B151"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tihan</surname><given-names>T.</given-names></name><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Holmes</surname><given-names>E.</given-names></name><name><surname>Burger</surname><given-names>P. C.</given-names></name><name><surname>Ozuysal</surname><given-names>S.</given-names></name><name><surname>Rushing</surname><given-names>E. J.</given-names></name></person-group><article-title>The prognostic value of histological grading of posterior fossa ependymomas in children: a Children's Oncology Group study and a review of prognostic factors</article-title><source><italic>Modern Pathology</italic></source><year>2008</year><volume>21</volume><issue>2</issue><fpage>165</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1038/modpathol.3800999</pub-id><pub-id pub-id-type="other">2-s2.0-38649109150</pub-id><pub-id pub-id-type="pmid">18084249</pub-id></element-citation></ref><ref id="B152"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>F. F.</given-names></name><name><surname>Bischof</surname><given-names>J. M.</given-names></name><name><surname>Vanin</surname><given-names>E. F.</given-names></name><etal/></person-group><article-title>Identification of microRNAs as potential prognostic markers in ependymoma</article-title><source><italic>PLoS ONE</italic></source><year>2011</year><volume>6</volume><issue>10</issue><pub-id pub-id-type="publisher-id">e25114</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0025114</pub-id></element-citation></ref><ref id="B153"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Tao</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate</article-title><source><italic>PLoS ONE</italic></source><year>2013</year><volume>8</volume><issue>4</issue><pub-id pub-id-type="publisher-id">e61858</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0061858</pub-id><pub-id pub-id-type="other">2-s2.0-84876177069</pub-id></element-citation></ref><ref id="B154"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bueno</surname><given-names>M. J.</given-names></name><name><surname>de Castro</surname><given-names>I. P.</given-names></name><name><surname>de Cedr&#x000f3;n</surname><given-names>M. G.</given-names></name><etal/></person-group><article-title>Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression</article-title><source><italic>Cancer Cell</italic></source><year>2008</year><volume>13</volume><issue>6</issue><fpage>496</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.04.018</pub-id><pub-id pub-id-type="other">2-s2.0-44449149903</pub-id><pub-id pub-id-type="pmid">18538733</pub-id></element-citation></ref><ref id="B155"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>R.</given-names></name><name><surname>Poy</surname><given-names>M. N.</given-names></name><name><surname>Stoffel</surname><given-names>M.</given-names></name><name><surname>Fuchs</surname><given-names>E.</given-names></name></person-group><article-title>A skin microRNA promotes differentiation by repressing &#x02018;stemness&#x02019;</article-title><source><italic>Nature</italic></source><year>2008</year><volume>452</volume><issue>7184</issue><fpage>225</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1038/nature06642</pub-id><pub-id pub-id-type="other">2-s2.0-40749111551</pub-id><pub-id pub-id-type="pmid">18311128</pub-id></element-citation></ref><ref id="B156"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakurai</surname><given-names>M.</given-names></name><name><surname>Miki</surname><given-names>Y.</given-names></name><name><surname>Masuda</surname><given-names>M.</given-names></name><etal/></person-group><article-title>LIN28: a regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer</article-title><source><italic>Journal of Steroid Biochemistry and Molecular Biology</italic></source><year>2012</year><volume>131</volume><issue>3&#x02013;5</issue><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.jsbmb.2011.10.007</pub-id><pub-id pub-id-type="other">2-s2.0-84862905774</pub-id><pub-id pub-id-type="pmid">22081076</pub-id></element-citation></ref><ref id="B157"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tezcan</surname><given-names>G.</given-names></name><name><surname>Tunca</surname><given-names>B.</given-names></name><name><surname>Bekar</surname><given-names>A.</given-names></name><etal/></person-group><article-title>microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells</article-title><source><italic>Cellular and Molecular Neurobiology</italic></source><year>2014</year><volume>34</volume><issue>5</issue><fpage>679</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1007/s10571-014-0050-0</pub-id><pub-id pub-id-type="other">2-s2.0-84897121286</pub-id><pub-id pub-id-type="pmid">24691539</pub-id></element-citation></ref><ref id="B158"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devor</surname><given-names>E. J.</given-names></name><name><surname>de Mik</surname><given-names>J. N.</given-names></name><name><surname>Ramachandran</surname><given-names>S.</given-names></name><name><surname>Goodheart</surname><given-names>M. J.</given-names></name><name><surname>Leslie</surname><given-names>K. K.</given-names></name></person-group><article-title>Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma</article-title><source><italic>Experimental and Therapeutic Medicine</italic></source><year>2012</year><volume>3</volume><issue>4</issue><fpage>677</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.3892/etm.2012.458</pub-id><pub-id pub-id-type="other">2-s2.0-84857011633</pub-id><pub-id pub-id-type="pmid">22969950</pub-id></element-citation></ref><ref id="B159"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haller</surname><given-names>F.</given-names></name><name><surname>von Heydebreck</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>J. D.</given-names></name><etal/></person-group><article-title>Localization- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31</article-title><source><italic>Journal of Pathology</italic></source><year>2010</year><volume>220</volume><issue>1</issue><fpage>71</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1002/path.2610</pub-id><pub-id pub-id-type="other">2-s2.0-73649145183</pub-id><pub-id pub-id-type="pmid">19768731</pub-id></element-citation></ref><ref id="B160"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasanthan</surname><given-names>P.</given-names></name><name><surname>Govindasamy</surname><given-names>V.</given-names></name><name><surname>Gnanasegaran</surname><given-names>N.</given-names></name><name><surname>Kunasekaran</surname><given-names>W.</given-names></name><name><surname>Musa</surname><given-names>S.</given-names></name><name><surname>Abu Kasim</surname><given-names>N. H.</given-names></name></person-group><article-title>Differential expression of basal microRNAs&#x02019; patterns in human dental pulp stem cells</article-title><source><italic>Journal of Cellular and Molecular Medicine</italic></source><year>2015</year><volume>19</volume><issue>3</issue><fpage>566</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1111/jcmm.12381</pub-id><pub-id pub-id-type="pmid">25475098</pub-id></element-citation></ref><ref id="B161"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneppenheim</surname><given-names>R.</given-names></name><name><surname>Fr&#x000fc;hwald</surname><given-names>M. C.</given-names></name><name><surname>Gesk</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Germline nonsense mutation and somatic inactivation of <italic>SMARCA4/BRG1</italic> in a family with rhabdoid tumor predisposition syndrome</article-title><source><italic>The American Journal of Human Genetics</italic></source><year>2010</year><volume>86</volume><issue>2</issue><fpage>279</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2010.01.013</pub-id><pub-id pub-id-type="other">2-s2.0-76049106059</pub-id></element-citation></ref><ref id="B162"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Versteege</surname><given-names>I.</given-names></name><name><surname>S&#x000e9;venet</surname><given-names>N.</given-names></name><name><surname>Lange</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer</article-title><source><italic>Nature</italic></source><year>1998</year><volume>394</volume><issue>6689</issue><fpage>203</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1038/28212</pub-id><pub-id pub-id-type="other">2-s2.0-2642647094</pub-id><pub-id pub-id-type="pmid">9671307</pub-id></element-citation></ref><ref id="B163"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Frequent overexpression of HMGA2 in human atypical teratoid/rhabdoid tumor and its correlation with let-7a3/let-7b miRNA</article-title><source><italic>Clinical Cancer Research</italic></source><year>2014</year><volume>20</volume><issue>5</issue><fpage>1179</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.ccr-13-1452</pub-id><pub-id pub-id-type="pmid">24423609</pub-id></element-citation></ref><ref id="B164"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yong</surname><given-names>S. L.</given-names></name><name><surname>Dutta</surname><given-names>A.</given-names></name></person-group><article-title>The tumor suppressor microRNA let-7 represses the HMGA2 oncogene</article-title><source><italic>Genes and Development</italic></source><year>2007</year><volume>21</volume><issue>9</issue><fpage>1025</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1101/gad.1540407</pub-id><pub-id pub-id-type="other">2-s2.0-34247565615</pub-id><pub-id pub-id-type="pmid">17437991</pub-id></element-citation></ref><ref id="B165"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayr</surname><given-names>C.</given-names></name><name><surname>Hemann</surname><given-names>M. T.</given-names></name><name><surname>Bartel</surname><given-names>D. P.</given-names></name></person-group><article-title>Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation</article-title><source><italic>Science</italic></source><year>2007</year><volume>315</volume><issue>5818</issue><fpage>1576</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1126/science.1137999</pub-id><pub-id pub-id-type="other">2-s2.0-33947431322</pub-id><pub-id pub-id-type="pmid">17322030</pub-id></element-citation></ref><ref id="B166"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>F.</given-names></name><name><surname>Yao</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>P.</given-names></name><etal/></person-group><article-title>let-7 regulates self renewal and tumorigenicity of breast cancer cells</article-title><source><italic>Cell</italic></source><year>2007</year><volume>131</volume><issue>6</issue><fpage>1109</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.10.054</pub-id><pub-id pub-id-type="other">2-s2.0-36849078711</pub-id><pub-id pub-id-type="pmid">18083101</pub-id></element-citation></ref><ref id="B167"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takamizawa</surname><given-names>J.</given-names></name><name><surname>Konishi</surname><given-names>H.</given-names></name><name><surname>Yanagisawa</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival</article-title><source><italic>Cancer Research</italic></source><year>2004</year><volume>64</volume><issue>11</issue><fpage>3753</fpage><lpage>3756</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.can-04-0637</pub-id><pub-id pub-id-type="other">2-s2.0-2542626605</pub-id><pub-id pub-id-type="pmid">15172979</pub-id></element-citation></ref><ref id="B168"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malek</surname><given-names>A.</given-names></name><name><surname>Bakhidze</surname><given-names>E.</given-names></name><name><surname>Noske</surname><given-names>A.</given-names></name><etal/></person-group><article-title>HMGA2 gene is a promising target for ovarian cancer silencing therapy</article-title><source><italic>International Journal of Cancer</italic></source><year>2008</year><volume>123</volume><issue>2</issue><fpage>348</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1002/ijc.23491</pub-id><pub-id pub-id-type="other">2-s2.0-44949237000</pub-id></element-citation></ref><ref id="B169"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yachnis</surname><given-names>A. T.</given-names></name><name><surname>Neubauer</surname><given-names>D.</given-names></name><name><surname>Muir</surname><given-names>D.</given-names></name></person-group><article-title>Characterization of a primary central nervous system atypical teratoid/rhabdoid tumor and derivative cell line: immunophenotype and neoplastic properties</article-title><source><italic>Journal of Neuropathology and Experimental Neurology</italic></source><year>1998</year><volume>57</volume><issue>10</issue><fpage>961</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1097/00005072-199810000-00008</pub-id><pub-id pub-id-type="other">2-s2.0-0031782644</pub-id><pub-id pub-id-type="pmid">9786246</pub-id></element-citation></ref><ref id="B170"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biegel</surname><given-names>J. A.</given-names></name></person-group><article-title>Molecular genetics of atypical teratoid/rhabdoid tumor</article-title><source><italic>Neurosurgical Focus</italic></source><year>2006</year><volume>20</volume><issue>4</issue><fpage>p. E11</fpage><pub-id pub-id-type="doi">10.3171/foc.2006.20.4.6</pub-id><pub-id pub-id-type="other">2-s2.0-33646104935</pub-id></element-citation></ref><ref id="B171"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parham</surname><given-names>D. M.</given-names></name><name><surname>Weeks</surname><given-names>D. A.</given-names></name><name><surname>Beckwith</surname><given-names>J. B.</given-names></name></person-group><article-title>The clinicopathologic spectrum of putative extrarenal rhabdoid tumors: an analysis of 42 cases studied with immunohistochemistry or electron microscopy</article-title><source><italic>American Journal of Surgical Pathology</italic></source><year>1994</year><volume>18</volume><issue>10</issue><fpage>1010</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1097/00000478-199410000-00005</pub-id><pub-id pub-id-type="other">2-s2.0-0028021314</pub-id><pub-id pub-id-type="pmid">8092393</pub-id></element-citation></ref><ref id="B172"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiou</surname><given-names>S.-H.</given-names></name><name><surname>Kao</surname><given-names>C.-L.</given-names></name><name><surname>Chen</surname><given-names>Y.-W.</given-names></name><etal/></person-group><article-title>Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor</article-title><source><italic>PLoS ONE</italic></source><year>2008</year><volume>3</volume><issue>5</issue><pub-id pub-id-type="publisher-id">e2090</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0002090</pub-id><pub-id pub-id-type="other">2-s2.0-47749106106</pub-id></element-citation></ref><ref id="B173"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>C.-L.</given-names></name><name><surname>Huang</surname><given-names>P.-I.</given-names></name><name><surname>Tsai</surname><given-names>P.-H.</given-names></name><etal/></person-group><article-title>Resveratrol-induced apoptosis and increased radiosensitivity in CD133-positive cells derived from atypical teratoid/rhabdoid tumor</article-title><source><italic>International Journal of Radiation Oncology Biology Physics</italic></source><year>2009</year><volume>74</volume><issue>1</issue><fpage>219</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2008.12.035</pub-id><pub-id pub-id-type="other">2-s2.0-64049084289</pub-id></element-citation></ref><ref id="B174"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>H.-I.</given-names></name><name><surname>Kao</surname><given-names>C.-L.</given-names></name><name><surname>Lee</surname><given-names>Y.-Y.</given-names></name><etal/></person-group><article-title>Differential expression profiling between atypical teratoid/rhabdoid and medulloblastoma tumor in vitro and in vivo using microarray analysis</article-title><source><italic>Child's Nervous System</italic></source><year>2010</year><volume>26</volume><issue>3</issue><fpage>293</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1007/s00381-009-1016-2</pub-id><pub-id pub-id-type="other">2-s2.0-77949269537</pub-id></element-citation></ref><ref id="B175"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asa</surname><given-names>S. L.</given-names></name><name><surname>Ezzat</surname><given-names>S.</given-names></name></person-group><article-title>The pathogenesis of pituitary tumours</article-title><source><italic>Nature Reviews Cancer</italic></source><year>2002</year><volume>2</volume><issue>11</issue><fpage>836</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1038/nrc926</pub-id><pub-id pub-id-type="other">2-s2.0-0036831826</pub-id></element-citation></ref><ref id="B176"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ezzat</surname><given-names>S.</given-names></name><name><surname>Asa</surname><given-names>S. L.</given-names></name></person-group><article-title>Mechanisms of disease: the pathogenesis of pituitary tumors</article-title><source><italic>Nature Clinical Practice Endocrinology and Metabolism</italic></source><year>2006</year><volume>2</volume><issue>4</issue><fpage>220</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1038/ncpendmet0159</pub-id><pub-id pub-id-type="other">2-s2.0-33646545708</pub-id></element-citation></ref><ref id="B177"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palumbo</surname><given-names>T.</given-names></name><name><surname>Faucz</surname><given-names>F. R.</given-names></name><name><surname>Azevedo</surname><given-names>M.</given-names></name><name><surname>Xekouki</surname><given-names>P.</given-names></name><name><surname>Iliopoulos</surname><given-names>D.</given-names></name><name><surname>Stratakis</surname><given-names>C. A.</given-names></name></person-group><article-title>Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway</article-title><source><italic>Oncogene</italic></source><year>2013</year><volume>32</volume><issue>13</issue><fpage>1651</fpage><lpage>1659</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.190</pub-id><pub-id pub-id-type="other">2-s2.0-84875886326</pub-id><pub-id pub-id-type="pmid">22614013</pub-id></element-citation></ref><ref id="B178"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butz</surname><given-names>H.</given-names></name><name><surname>Lik&#x000f3;</surname><given-names>I.</given-names></name><name><surname>Czirj&#x000e1;k</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas</article-title><source><italic>Journal of Clinical Endocrinology and Metabolism</italic></source><year>2010</year><volume>95</volume><issue>10</issue><fpage>E181</fpage><lpage>E191</lpage><pub-id pub-id-type="doi">10.1210/jc.2010-0581</pub-id><pub-id pub-id-type="other">2-s2.0-77957782177</pub-id><pub-id pub-id-type="pmid">20668041</pub-id></element-citation></ref><ref id="B179"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGowan</surname><given-names>C. H.</given-names></name><name><surname>Russell</surname><given-names>P.</given-names></name></person-group><article-title>Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15</article-title><source><italic>The EMBO Journal</italic></source><year>1993</year><volume>12</volume><issue>1</issue><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="other">2-s2.0-0027510249</pub-id><pub-id pub-id-type="pmid">8428596</pub-id></element-citation></ref><ref id="B180"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis-Dusenbery</surname><given-names>B. N.</given-names></name><name><surname>Hata</surname><given-names>A.</given-names></name></person-group><article-title>Mechanisms of control of microRNA biogenesis</article-title><source><italic>Journal of Biochemistry</italic></source><year>2010</year><volume>148</volume><issue>4</issue><fpage>381</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1093/jb/mvq096</pub-id><pub-id pub-id-type="other">2-s2.0-77958050722</pub-id><pub-id pub-id-type="pmid">20833630</pub-id></element-citation></ref><ref id="B181"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotani</surname><given-names>A.</given-names></name><name><surname>Ha</surname><given-names>D.</given-names></name><name><surname>Schotte</surname><given-names>D.</given-names></name><name><surname>Den Boer</surname><given-names>M. L.</given-names></name><name><surname>Armstrong</surname><given-names>S. A.</given-names></name><name><surname>Lodish</surname><given-names>H. F.</given-names></name></person-group><article-title>A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells</article-title><source><italic>Cell Cycle</italic></source><year>2010</year><volume>9</volume><issue>6</issue><fpage>1037</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.4161/cc.9.6.11011</pub-id><pub-id pub-id-type="other">2-s2.0-77953528169</pub-id><pub-id pub-id-type="pmid">20237425</pub-id></element-citation></ref><ref id="B182"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maitra</surname><given-names>A.</given-names></name><name><surname>Wistuba</surname><given-names>I. I.</given-names></name><name><surname>Washington</surname><given-names>C.</given-names></name><etal/></person-group><article-title>High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss</article-title><source><italic>American Journal of Pathology</italic></source><year>2001</year><volume>159</volume><issue>1</issue><fpage>119</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/s0002-9440(10)61679-3</pub-id><pub-id pub-id-type="other">2-s2.0-0035406393</pub-id><pub-id pub-id-type="pmid">11438460</pub-id></element-citation></ref><ref id="B183"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Fu</surname><given-names>W.</given-names></name><name><surname>Wo</surname><given-names>L.</given-names></name><name><surname>Shu</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name></person-group><article-title>MiR-128 and its target genes in tumorigenesis and metastasis</article-title><source><italic>Experimental Cell Research</italic></source><year>2013</year><volume>319</volume><issue>20</issue><fpage>3059</fpage><lpage>3064</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2013.07.031</pub-id><pub-id pub-id-type="other">2-s2.0-84887139031</pub-id><pub-id pub-id-type="pmid">23958464</pub-id></element-citation></ref><ref id="B184"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mi</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>M.</given-names></name><etal/></person-group><article-title>MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2007</year><volume>104</volume><issue>50</issue><fpage>19971</fpage><lpage>19976</lpage><pub-id pub-id-type="doi">10.1073/pnas.0709313104</pub-id><pub-id pub-id-type="other">2-s2.0-38049123402</pub-id><pub-id pub-id-type="pmid">18056805</pub-id></element-citation></ref><ref id="B185"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottoni</surname><given-names>A.</given-names></name><name><surname>Zatelli</surname><given-names>M. C.</given-names></name><name><surname>Ferrcin</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas</article-title><source><italic>Journal of Cellular Physiology</italic></source><year>2007</year><volume>210</volume><issue>2</issue><fpage>370</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1002/jcp.20832</pub-id><pub-id pub-id-type="other">2-s2.0-33845608588</pub-id><pub-id pub-id-type="pmid">17111382</pub-id></element-citation></ref><ref id="B186"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stegh</surname><given-names>A. H.</given-names></name><name><surname>Schickling</surname><given-names>O.</given-names></name><name><surname>Ehret</surname><given-names>A.</given-names></name><etal/></person-group><article-title>DEDD, a novel death effector domain-containing protein, targeted to the nucleolus</article-title><source><italic>The EMBO Journal</italic></source><year>1998</year><volume>17</volume><issue>20</issue><fpage>5974</fpage><lpage>5986</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.20.5974</pub-id><pub-id pub-id-type="other">2-s2.0-0032531817</pub-id><pub-id pub-id-type="pmid">9774341</pub-id></element-citation></ref><ref id="B187"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>Z.</given-names></name><name><surname>He</surname><given-names>D.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Differential expression of microRNAs in GH-secreting pituitary adenomas</article-title><source><italic>Diagnostic Pathology</italic></source><year>2010</year><volume>5</volume><issue>1, article 79</issue><pub-id pub-id-type="doi">10.1186/1746-1596-5-79</pub-id></element-citation></ref><ref id="B188"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salehi</surname><given-names>F.</given-names></name><name><surname>Kovacs</surname><given-names>K.</given-names></name><name><surname>Scheithauer</surname><given-names>B. W.</given-names></name><name><surname>Lloyd</surname><given-names>R. V.</given-names></name><name><surname>Cusimano</surname><given-names>M.</given-names></name></person-group><article-title>Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update</article-title><source><italic>Endocrine-Related Cancer</italic></source><year>2008</year><volume>15</volume><issue>3</issue><fpage>721</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1677/erc-08-0012</pub-id><pub-id pub-id-type="other">2-s2.0-53849096004</pub-id><pub-id pub-id-type="pmid">18753362</pub-id></element-citation></ref><ref id="B189"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhi</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Deng</surname><given-names>D.</given-names></name><etal/></person-group><article-title>MiR-181b-5p downregulates NOVA1 to suppress proliferation, migration and invasion and promote apoptosis in astrocytoma</article-title><source><italic>PLoS ONE</italic></source><year>2014</year><volume>9</volume><issue>10</issue><pub-id pub-id-type="publisher-id">e109124</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0109124</pub-id></element-citation></ref><ref id="B193"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardridge</surname><given-names>W. M.</given-names></name></person-group><article-title>shRNA and siRNA delivery to the brain</article-title><source><italic>Advanced Drug Delivery Reviews</italic></source><year>2007</year><volume>59</volume><issue>2-3</issue><fpage>141</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2007.03.008</pub-id><pub-id pub-id-type="other">2-s2.0-34248679586</pub-id><pub-id pub-id-type="pmid">17434235</pub-id></element-citation></ref><ref id="B194"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>M. E.</given-names></name><name><surname>Drummond</surname><given-names>D. C.</given-names></name><name><surname>Kirpotin</surname><given-names>D. B.</given-names></name><etal/></person-group><article-title>Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery</article-title><source><italic>Gene Therapy</italic></source><year>2006</year><volume>13</volume><issue>7</issue><fpage>646</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3302699</pub-id><pub-id pub-id-type="other">2-s2.0-33645107882</pub-id><pub-id pub-id-type="pmid">16341056</pub-id></element-citation></ref><ref id="B195"><label>183</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>R.</given-names></name><name><surname>Krauze</surname><given-names>M. T.</given-names></name><name><surname>Noble</surname><given-names>C. O.</given-names></name><etal/></person-group><article-title>Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model</article-title><source><italic>Neuro-Oncology</italic></source><year>2006</year><volume>8</volume><issue>3</issue><fpage>205</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1215/15228517-2006-001</pub-id><pub-id pub-id-type="other">2-s2.0-33750821464</pub-id><pub-id pub-id-type="pmid">16723630</pub-id></element-citation></ref><ref id="B101"><label>184</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Shi</surname><given-names>D.</given-names></name><etal/></person-group><article-title>MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2</article-title><source><italic>Oncology Reports</italic></source><year>2010</year><volume>23</volume><issue>4</issue><fpage>997</fpage><lpage>1003</lpage><pub-id pub-id-type="other">2-s2.0-77949445582</pub-id><pub-id pub-id-type="pmid">20204284</pub-id></element-citation></ref><ref id="B106"><label>185</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma</article-title><source><italic>Oncotarget</italic></source><year>2014</year><volume>5</volume><issue>14</issue><fpage>5416</fpage><lpage>5427</lpage><pub-id pub-id-type="pmid">24980823</pub-id></element-citation></ref><ref id="B107"><label>186</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Liao</surname><given-names>X.</given-names></name><name><surname>Wong</surname><given-names>C.</given-names></name></person-group><article-title>Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG</article-title><source><italic>International Journal of Cancer</italic></source><year>2010</year><volume>126</volume><issue>4</issue><fpage>1029</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1002/ijc.24823</pub-id><pub-id pub-id-type="other">2-s2.0-74049092646</pub-id></element-citation></ref><ref id="B100"><label>187</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.-Z.</given-names></name><name><surname>Zhang</surname><given-names>J.-X.</given-names></name><name><surname>Zhang</surname><given-names>A.-L.</given-names></name><etal/></person-group><article-title>MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma</article-title><source><italic>Molecular Cancer</italic></source><year>2010</year><volume>9, article 229</volume><pub-id pub-id-type="doi">10.1186/1476-4598-9-229</pub-id><pub-id pub-id-type="other">2-s2.0-77956464355</pub-id></element-citation></ref><ref id="B102"><label>188</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>C.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Hong</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Xue</surname><given-names>Y.</given-names></name></person-group><article-title>MiR-21 up-regulation mediates glioblastoma cancer stem cells apoptosis and proliferation by targeting FASLG</article-title><source><italic>Molecular Biology Reports</italic></source><year>2015</year><volume>42</volume><issue>3</issue><fpage>721</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1007/s11033-014-3820-3</pub-id><pub-id pub-id-type="pmid">25394756</pub-id></element-citation></ref><ref id="B103"><label>189</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>B. X.</given-names></name><name><surname>Liu</surname><given-names>Z. H.</given-names></name><name><surname>Li</surname><given-names>Z. J.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Deng</surname><given-names>Y. F.</given-names></name></person-group><article-title>miR-21 induces cell proliferation and suppresses the chemosensitivity in glioblastoma cells via downregulation of FOXO1</article-title><source><italic>International Journal of Clinical and Experimental Medicine</italic></source><year>2014</year><volume>7</volume><issue>8</issue><fpage>2060</fpage><lpage>2066</lpage><pub-id pub-id-type="pmid">25232387</pub-id></element-citation></ref><ref id="B104"><label>190</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C. H.</given-names></name><name><surname>Yue</surname><given-names>J.</given-names></name><name><surname>Pfeffer</surname><given-names>S. R.</given-names></name><etal/></person-group><article-title>MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3)</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2014</year><volume>289</volume><issue>36</issue><fpage>25079</fpage><lpage>25087</lpage><pub-id pub-id-type="doi">10.1074/jbc.m114.593863</pub-id><pub-id pub-id-type="pmid">25059666</pub-id></element-citation></ref><ref id="B105"><label>191</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C. H.</given-names></name><name><surname>Pfeffer</surname><given-names>S. R.</given-names></name><name><surname>Sims</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The oncogenic microRNA-21 inhibits the tumor suppressive activity of FBXO11 to promote tumorigenesis</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2015</year><volume>290</volume><issue>10</issue><fpage>6037</fpage><lpage>6046</lpage><pub-id pub-id-type="doi">10.1074/jbc.m114.632125</pub-id><pub-id pub-id-type="pmid">25589783</pub-id></element-citation></ref><ref id="B108"><label>192</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pateras</surname><given-names>I. S.</given-names></name><name><surname>Apostolopoulou</surname><given-names>K.</given-names></name><name><surname>Niforou</surname><given-names>K.</given-names></name><name><surname>Kotsinas</surname><given-names>A.</given-names></name><name><surname>Gorgoulis</surname><given-names>V. G.</given-names></name></person-group><article-title>p57KIP2: &#x02018;kip&#x02019;ing the cell under control</article-title><source><italic>Molecular Cancer Research</italic></source><year>2009</year><volume>7</volume><issue>12</issue><fpage>1902</fpage><lpage>1919</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.mcr-09-0317</pub-id><pub-id pub-id-type="other">2-s2.0-73849090298</pub-id><pub-id pub-id-type="pmid">19934273</pub-id></element-citation></ref><ref id="B190"><label>193</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaral</surname><given-names>F. C.</given-names></name><name><surname>Torres</surname><given-names>N.</given-names></name><name><surname>Saggioro</surname><given-names>F.</given-names></name><etal/></person-group><article-title>MicroRNAs differentially expressed in ACTH-secreting pituitary tumors</article-title><source><italic>Journal of Clinical Endocrinology and Metabolism</italic></source><year>2009</year><volume>94</volume><issue>1</issue><fpage>320</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1210/jc.2008-1451</pub-id><pub-id pub-id-type="other">2-s2.0-58149381996</pub-id><pub-id pub-id-type="pmid">18840638</pub-id></element-citation></ref><ref id="B191"><label>194</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catania</surname><given-names>A.</given-names></name><name><surname>Maira</surname><given-names>F.</given-names></name><name><surname>Skarmoutsou</surname><given-names>E.</given-names></name><name><surname>D'Amico</surname><given-names>F.</given-names></name><name><surname>Abounader</surname><given-names>R.</given-names></name><name><surname>Mazzarino</surname><given-names>M. C.</given-names></name></person-group><article-title>Insight into the role of microRNAs in brain tumors (review)</article-title><source><italic>International Journal of Oncology</italic></source><year>2012</year><volume>40</volume><issue>3</issue><fpage>605</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.3892/ijo.2011.1305</pub-id><pub-id pub-id-type="other">2-s2.0-84857164148</pub-id><pub-id pub-id-type="pmid">22179098</pub-id></element-citation></ref><ref id="B192"><label>195</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gentilin</surname><given-names>E.</given-names></name><name><surname>Tagliati</surname><given-names>F.</given-names></name><name><surname>Filieri</surname><given-names>C.</given-names></name><etal/></person-group><article-title>MiR-26a plays an important role in cell cycle regulation in ACTH-secreting pituitary adenomas by modulating protein kinase Cdelta</article-title><source><italic>Endocrinology</italic></source><year>2013</year><volume>154</volume><issue>5</issue><fpage>1690</fpage><lpage>1700</lpage><pub-id pub-id-type="doi">10.1210/en.2012-2070</pub-id><pub-id pub-id-type="other">2-s2.0-84876748531</pub-id><pub-id pub-id-type="pmid">23525216</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>miRNAs regulating BTICs in gliomas and GBM stem cells.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">MicroRNAs</th><th align="center" rowspan="1" colspan="1">Targets</th><th align="center" rowspan="1" colspan="1">Expression in GSCs</th><th align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" colspan="4" rowspan="1">Adult patients</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-128</td><td align="center" rowspan="1" colspan="1">RTKs, EGFR, PDGFR, Akt, Bmi1, HIF-1, VEGF, E2F3</td><td align="center" rowspan="1" colspan="1">Downregulated </td><td align="center" rowspan="1" colspan="1">[<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B59" ref-type="bibr">59</xref>&#x02013;<xref rid="B62" ref-type="bibr">62</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-181a, b, c</td><td align="center" rowspan="1" colspan="1">Bcl-2, </td><td align="center" rowspan="1" colspan="1">Downregulated </td><td align="center" rowspan="1" colspan="1">[<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B101" ref-type="bibr">184</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-125b</td><td align="center" rowspan="1" colspan="1">CDK6, CDC25A, E2F2, MMP-2, MMP-9, RECK, TIMP3</td><td align="center" rowspan="1" colspan="1">Downregulated </td><td align="center" rowspan="1" colspan="1">[<xref rid="B56" ref-type="bibr">56</xref>&#x02013;<xref rid="B58" ref-type="bibr">58</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-143</td><td align="center" rowspan="1" colspan="1">N-RAS, PI3K/Akt, MAPK/ERK </td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B106" ref-type="bibr">185</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-153</td><td align="center" rowspan="1" colspan="1">Bcl-2, Mcl-1</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B64" ref-type="bibr">64</xref>, <xref rid="B107" ref-type="bibr">186</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-7</td><td align="center" rowspan="1" colspan="1">EGFR, Akt</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B65" ref-type="bibr">65</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-145</td><td align="center" rowspan="1" colspan="1">ABCG2</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B66" ref-type="bibr">66</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-34a</td><td align="center" rowspan="1" colspan="1">Akt, Wnt pathway, c-Met, Notch-1, Notch-2</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B69" ref-type="bibr">69</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-34c-3p, 5p</td><td align="center" rowspan="1" colspan="1">Notch-2</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B70" ref-type="bibr">70</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-146a</td><td align="center" rowspan="1" colspan="1">Notch-1</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B71" ref-type="bibr">71</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-326</td><td align="center" rowspan="1" colspan="1">Notch-1, Notch-2, PKM2</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B73" ref-type="bibr">73</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-107</td><td align="center" rowspan="1" colspan="1">Notch-2, MMP-12</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B72" ref-type="bibr">72</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-622</td><td align="center" rowspan="1" colspan="1">ATF2</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B74" ref-type="bibr">74</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-152</td><td align="center" rowspan="1" colspan="1">KLF4</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B75" ref-type="bibr">75</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-218</td><td align="center" rowspan="1" colspan="1">Bmi1</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B76" ref-type="bibr">76</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-124</td><td align="center" rowspan="1" colspan="1">SNAI2, CDK6</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-137</td><td align="center" rowspan="1" colspan="1">RTVP-1, c-KIT, YBX1, Akt2, CDC42, CDK6, TGF<italic>&#x003b2;</italic>2</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-451</td><td align="center" rowspan="1" colspan="1">PI3K/Akt pathway</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B81" ref-type="bibr">81</xref>, <xref rid="B82" ref-type="bibr">82</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-200 family</td><td align="center" rowspan="1" colspan="1">CREB1, RAB family, SIM2-s</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B83" ref-type="bibr">83</xref>&#x02013;<xref rid="B86" ref-type="bibr">86</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-221, miR-222</td><td align="center" rowspan="1" colspan="1">p27 and p57</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B100" ref-type="bibr">187</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-21</td><td align="center" rowspan="1" colspan="1">FASLG, FOXO1, IGFBP3, FBXO11</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B102" ref-type="bibr">188</xref>&#x02013;<xref rid="B105" ref-type="bibr">191</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-10 family</td><td align="center" rowspan="1" colspan="1">CUB, SUSHI</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B88" ref-type="bibr">88</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-17-92 cluster</td><td align="center" rowspan="1" colspan="1">CTGF, PTEN</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B92" ref-type="bibr">92</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-9</td><td align="center" rowspan="1" colspan="1">CAMTA1</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B90" ref-type="bibr">90</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-300</td><td align="center" rowspan="1" colspan="1">SH3GL2</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B95" ref-type="bibr">95</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-582-5p</td><td align="center" rowspan="1" colspan="1">Caspase3, caspase9, Bim</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B94" ref-type="bibr">94</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-363</td><td align="center" rowspan="1" colspan="1">Caspase3, caspase9, Bim</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B94" ref-type="bibr">94</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-1275</td><td align="center" rowspan="1" colspan="1">Claudin11</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B96" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="center" colspan="4" rowspan="1">Pediatric patients</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-129</td><td align="center" rowspan="1" colspan="1">Undefined</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B99" ref-type="bibr">99</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-142-5p</td><td align="center" rowspan="1" colspan="1">Undefined</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B99" ref-type="bibr">99</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-25 </td><td align="center" rowspan="1" colspan="1">P57</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B108" ref-type="bibr">192</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-17-92 </td><td align="center" rowspan="1" colspan="1">PTEN, RB1</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B92" ref-type="bibr">92</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>miRNAs regulating BTICs in MB.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">MicroRNAs</th><th align="center" rowspan="1" colspan="1">Targets</th><th align="center" rowspan="1" colspan="1">Expression in MB/BTICs of MB</th><th align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">miR-124</td><td align="center" rowspan="1" colspan="1">CDK6</td><td align="center" rowspan="2" colspan="1">Reduced</td><td align="center" rowspan="2" colspan="1">[<xref rid="B119" ref-type="bibr">110</xref>, <xref rid="B120" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">SLC16A1</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-125b</td><td align="center" rowspan="3" colspan="1">Shh signaling pathway</td><td align="center" rowspan="1" colspan="1">Reduced</td><td align="center" rowspan="1" colspan="1">[<xref rid="B117" ref-type="bibr">108</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-324</td><td align="center" rowspan="1" colspan="1">Reduced</td><td align="center" rowspan="1" colspan="1">[<xref rid="B117" ref-type="bibr">108</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-326</td><td align="center" rowspan="1" colspan="1">Reduced </td><td align="center" rowspan="1" colspan="1">[<xref rid="B117" ref-type="bibr">108</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-193</td><td align="center" rowspan="2" colspan="1">Wnt signaling pathway</td><td align="center" rowspan="1" colspan="1">Reduced</td><td align="center" rowspan="1" colspan="1">[<xref rid="B133" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-224</td><td align="center" rowspan="1" colspan="1">Reduced</td><td align="center" rowspan="1" colspan="1">[<xref rid="B133" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-1280</td><td align="center" rowspan="1" colspan="1">JAG2</td><td align="center" rowspan="1" colspan="1">Reduced</td><td align="center" rowspan="1" colspan="1">[<xref rid="B135" ref-type="bibr">120</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-218</td><td align="center" rowspan="1" colspan="1">CDK6, RICTOR, CTSB</td><td align="center" rowspan="1" colspan="1">Reduced</td><td align="center" rowspan="1" colspan="1">[<xref rid="B123" ref-type="bibr">112</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-199b</td><td align="center" rowspan="1" colspan="1">HES1</td><td align="center" rowspan="1" colspan="1">Reduced</td><td align="center" rowspan="1" colspan="1">[<xref rid="B124" ref-type="bibr">113</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-34a</td><td align="center" rowspan="1" colspan="1">c-MET, Notch-1, Notch-2, CDK6, MAGE-A, DLL2</td><td align="center" rowspan="1" colspan="1">Reduced</td><td align="center" rowspan="1" colspan="1">[<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B127" ref-type="bibr">116</xref>, <xref rid="B128" ref-type="bibr">117</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-9</td><td align="center" rowspan="2" colspan="1">t-TrkC</td><td align="center" rowspan="1" colspan="1">Reduced </td><td align="center" rowspan="1" colspan="1">[<xref rid="B118" ref-type="bibr">109</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-125</td><td align="center" rowspan="1" colspan="1">Reduced </td><td align="center" rowspan="1" colspan="1">[<xref rid="B118" ref-type="bibr">109</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-128a/b</td><td align="center" rowspan="1" colspan="1">Bmi1</td><td align="center" rowspan="1" colspan="1">Reduced</td><td align="center" rowspan="1" colspan="1">[<xref rid="B118" ref-type="bibr">109</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-135a</td><td align="center" rowspan="1" colspan="1">Arhgef6 </td><td align="center" rowspan="1" colspan="1">Reduced</td><td align="center" rowspan="1" colspan="1">[<xref rid="B136" ref-type="bibr">121</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-21</td><td align="center" rowspan="1" colspan="1">PDCD4</td><td align="center" rowspan="1" colspan="1">Increased</td><td align="center" rowspan="1" colspan="1">[<xref rid="B129" ref-type="bibr">124</xref>, <xref rid="B132" ref-type="bibr">127</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-182/96/183</td><td align="center" rowspan="1" colspan="1">Wnt signaling pathway</td><td align="center" rowspan="1" colspan="1">Increased</td><td align="center" rowspan="1" colspan="1">[<xref rid="B129" ref-type="bibr">124</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-17/92</td><td align="center" rowspan="1" colspan="1">PTEN, Shh pathway</td><td align="center" rowspan="1" colspan="1">Increased</td><td align="center" rowspan="1" colspan="1">[<xref rid="B118" ref-type="bibr">109</xref>, <xref rid="B121" ref-type="bibr">122</xref>, <xref rid="B122" ref-type="bibr">123</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-142</td><td align="center" rowspan="1" colspan="1">GATA1, TAL1/E47</td><td align="center" rowspan="1" colspan="1">Increased</td><td align="center" rowspan="1" colspan="1">[<xref rid="B130" ref-type="bibr">125</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">miR-30b/30d</td><td align="center" rowspan="1" colspan="1">Undefined</td><td align="center" rowspan="1" colspan="1">Increased</td><td align="center" rowspan="1" colspan="1">[<xref rid="B137" ref-type="bibr">128</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>miRNAs regulating BTICs in other CNS tumours.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Tumour</th><th align="center" rowspan="1" colspan="1">miRNA</th><th align="center" rowspan="1" colspan="1">Target/putative target</th><th align="center" rowspan="1" colspan="1">Expression level</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="14" colspan="1">Pituitary adenoma</td><td align="center" rowspan="1" colspan="1">miRNA-16-1</td><td align="center" rowspan="1" colspan="1">BCL1</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B143" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Let-7</td><td align="center" rowspan="1" colspan="1">HMGA2</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B165" ref-type="bibr">156</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-128</td><td align="center" rowspan="1" colspan="1">Bmi1</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B177" ref-type="bibr">168</xref>&#x02013;<xref rid="B179" ref-type="bibr">170</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-143</td><td align="center" rowspan="1" colspan="1">ERK5</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B178" ref-type="bibr">169</xref>, <xref rid="B190" ref-type="bibr">193</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-126</td><td align="center" rowspan="1" colspan="1">PTTG1</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B187" ref-type="bibr">178</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-381</td><td align="center" rowspan="1" colspan="1">PTTG1</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B187" ref-type="bibr">178</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-132, miR-136, miR-127, miR-129, miR-203, miR-134, miR-127, miR-141, miR-145</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B177" ref-type="bibr">168</xref>, <xref rid="B185" ref-type="bibr">176</xref>, <xref rid="B191" ref-type="bibr">194</xref>] </td></tr><tr><td align="center" rowspan="1" colspan="1">miRNA-128a</td><td align="center" rowspan="1" colspan="1">Wee1</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B178" ref-type="bibr">169</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">miRNA-155</td><td align="center" rowspan="1" colspan="1">Wee1</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B178" ref-type="bibr">169</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">miRNA-516-3p</td><td align="center" rowspan="1" colspan="1">Wee1</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B177" ref-type="bibr">168</xref>, <xref rid="B178" ref-type="bibr">169</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-26b</td><td align="center" rowspan="1" colspan="1">PTEN</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B177" ref-type="bibr">168</xref>&#x02013;<xref rid="B179" ref-type="bibr">170</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-26a</td><td align="center" rowspan="1" colspan="1">PKCd</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B192" ref-type="bibr">195</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-212</td><td align="center" rowspan="1" colspan="1">DEDD</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B185" ref-type="bibr">176</xref>, <xref rid="B186" ref-type="bibr">177</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-150, miR-152, miR-191, miR-192 miR-23a, miR-23b, miR-24-2, miR-137</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B177" ref-type="bibr">168</xref>, <xref rid="B185" ref-type="bibr">176</xref>, <xref rid="B191" ref-type="bibr">194</xref>] </td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="2" colspan="1">Craniopharyngioma</td><td align="center" rowspan="1" colspan="1">miR-141, miR-16, miR-449, miR-145, let-7a, miR-143, miR-23b, miR-15a, miR-24-2</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B143" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-150</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B143" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="4" colspan="1">AT/RT</td><td align="center" rowspan="1" colspan="1">let-7b</td><td align="center" rowspan="1" colspan="1">HMGA2</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B163" ref-type="bibr">154</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">let-7a3</td><td align="center" rowspan="1" colspan="1">HMGA2</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B163" ref-type="bibr">154</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-140, miR-139, miR-153, miR-376b</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B163" ref-type="bibr">154</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-520b, miR-629, miR-221, miR-498, miR-373</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B163" ref-type="bibr">154</xref>]</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="2" colspan="1">Pilocytic astrocytoma</td><td align="center" rowspan="1" colspan="1">miR-93, miR-135a, miR-129, miR-135b, miR-106b, miR-181b-5p</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B189" ref-type="bibr">180</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-432, miR-29a, miR-138, miR-299-5p, miR-34a</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B99" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="2" colspan="1">Ependymoma</td><td align="center" rowspan="1" colspan="1">miR-485-5p, miR-383, miR-139, miR-323, miR-433, miR-137, miR-138, miR-124a, miR-181d, miR-193b</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Downregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B152" ref-type="bibr">143</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">miR-34a, miR-135a, miR-17-5p, miR-10a, miR-19a, miR-19b, miR-20a, miR-21, miR-32, miR-34c, miR-34b, miR-200b, miR-200a, miR-483miR-106b, miR-130a, miR-135a, miR-142-3, miR-193, miR-210, miR-301, miR-449b, miR-502, miR-518b, miR-551b, miR-565, miR-591, miR-594, miR-601</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Upregulated</td><td align="center" rowspan="1" colspan="1">[<xref rid="B99" ref-type="bibr">99</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>